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ABSTRACT 
Novel Aminoglycosides: Bioactive Properties and Mechanism of Action 
by 
Sanjib K. Shrestha, Doctor of Philosophy 
Utah State University, 2013 
Major Professor: Dr. Jon Y. Takemoto 
Department: Biology 
Fungicide discovery is relatively neglected when compared to the investment in 
the development of antibacterial, antiviral, and anti-cancer therapeutics. Due to extensive 
use of currently available fungicides in agriculture and medicine, resistance is emerging 
among plant and animal pathogenic fungi. This necessitates the search for novel 
antifungal agents that are effective and less toxic and that do not promote resistance. 
FG08 and K20 are novel aminoglycoside analogs synthesized from kanamycin B 
and A, respectively. The antimicrobial properties of these analogs were tested in vitro 
against a wide range of agriculturally and clinically important fungal pathogens. Both 
compounds showed broad-spectrum antifungal properties, but they did not inhibit 
bacteria such as Escherichia coli and Staphylococcus aureus. The hemolytic activities 
and cytotoxicities of FG08 and K20 were also evaluated. They showed no toxicity or 
lowered toxicity against animal cells at their antifungal minimum inhibitory 
concentrations (MICs). 
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The fungicidal mechanisms of action of FG08 and K20 were examined using 
intact cells of Saccharomyces cerevisiae, Cryptococcus neoformans, hyphae of Fusarium 
graminearum. FG08 and K20 caused SYTOX Green dye uptake and potassium efflux by 
intact cells, indicating that they increase plasma membrane permeability. FG08 and K20 
also caused leakage of pre-loaded calcein from small unilamellar vesicles (SUVs) 
composed of lipids that mimic the lipid composition of fungal membranes, further 
suggesting increased membrane permeability as their mechanism of action.  
The synergistic interactions of K20 with six azoles (such as itraconazole, and 
fluconazole) were investigated against a wide array of fungal pathogens. The in vitro 
results revealed strong synergy between K20 and azoles against plant and human 
pathogenic fungi. Their synergies were furthered confirmed by time kill curves and disk 
diffusion methods. 
In conclusion, FG08 and K20 are broad-spectrum antifungal agents that do not 
inhibit bacteria. At their antifungal MICs, they are not toxic to animal cells, but they 
inhibit fungi by interacting with the fungal plasma membrane, leading to pore formation. 
These novel aminoglycoside analogs appear attractive for applications as fungicides in 
agriculture and medicine.  
(151 pages) 
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PUBLIC ABSTRACT 
Novel Aminoglycosides: Bioactive Properties and Mechanism of Action 
by 
Sanjib K. Shrestha, Doctor of Philosophy 
Utah State University, 2013 
Major Professor: Dr. Jon Y. Takemoto 
Department: Biology 
More than 90% of crop diseases are due to fungal infections, which globally cause 
enormous economic losses. Fungal infections in humans and animals have also become a 
serious concern, especially in immunocompromised individuals. However, only a few 
new fungicides have been introduced since the mid-1980s, and concerns with inconsistent 
and declining effectiveness due to resistance, environmental impacts, animal and human 
toxicity, and costs continue to challenge the use of available fungicides. There is a serious 
and persistent need for new antifungal agents that are more effective, eco-friendly, less 
toxic, and available at reasonable cost.  
This study reveals two novel aminoglycosides, FG08 and K20, that are 
synthesized from kanamycin B and A, respectively. Kanamycin B and A are 
aminoglycoside antibiotics that kill bacteria. In contrast, FG08 and K20 showed broad-
spectrum antifungal activities against a wide range of agriculturally and clinically 
important fungal pathogens, but they did not inhibit bacteria. They showed no or lowered 
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toxicities against animal cells at their antifungal minimum inhibitory concentrations 
(MICs). They inhibit fungi by interacting with the fungal plasma membrane, leading to 
pore formation. K20 can be produced on a large scale, which makes it feasible to develop 
as a fungicide for commercial application. Additionally, K20 showed synergistic 
antifungal interaction with azoles against various fungi. Azoles are today’s most widely 
used antifungal agents to treat fungal infections in agriculture and medicine. In 
conclusion, this research has helped discover a new class of broad spectrum fungicides, 
which appear attractive for application as crop disease protectants and therapeutics 
against serious fungal infections in immunocompromised humans. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
THE FUNGI 
Fungi are ubiquitous organisms present in the environment that are unavoidable. 
It is estimated that there are 250,000 to 300,000 species of fungi [1]. In nature, they play 
important roles in the carbon cycle where they act as decomposers of organic materials 
along with other microorganisms such as bacteria. Fungi are either unicellular or 
multicellular and can be grouped on the basis of morphology as either yeasts or molds. 
Yeasts are a unicellular form of fungi that can divide by budding. They produce round, 
pasty or mucoid colonies on solid medium. In contrast, molds are multicellular, 
multinucleated, filamentous forms of fungi that produce thread-like hyphae that 
intermingle to form a mat-like structure called a mycelium [2]. 
Fungi are able to grow parasitically on plants, animals, humans and other fungi. 
Plant pathogenic fungi can cause severe damage and loss to agriculture, causing diseases 
such as late blight of potato, chestnut blight and Dutch elm diseases. More than 90% of 
crop diseases are due to fungal infections which globally cause enormous economic 
losses. Fungal diseases destroy > 125 million tons/year of the top five foods (rice, wheat, 
maize, potatoes and soybean) that could feed more than 600 million people [3]. Fungi 
have long been understood to be a widespread threat to plants [3]; however, appreciation 
of their threats to animal and human health is increasing due to increasing occurrences of 
systemic mycoses that are becoming significant causes for morbidity and mortality in 
humans. Approximately 150 species of fungi are known as primary pathogens in humans, 
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several of which may be fatal if left untreated. Candida species have been reported as the 
fourth most common cause of nosocomial bloodstream infections in the United States; 
however, other fungi such as Cryptococcus spp., Aspergillus spp., Fusarium spp., and 
Scedosporium spp. are emerging pathogens that pose direct threats to human health [4]. 
The frequency of invasive fungal infections has increased due to a growing 
immunocompromised population, as a result of increases in rates of HIV infection, organ 
transplantation and cancer chemotherapy [5]. 
ANTIFUNGAL AGENTS 
Fungicides are biocidal chemical compounds or biological organisms that 
specifically kill fungi. Fungicides have been used extensively for over 200 years to 
protect plants against diseases caused by fungi. Direct application of fungicides has been 
a major way to control fungal diseases and it plays an important role in crop protection. 
More than 150 different fungicidal compounds are currently used with a global market 
value of about 6 billion U.S. dollars, accounting for almost 20% of the agrochemicals 
market [6]. According to the U.S. Environmental Protection Agency (EPA) 
approximately 244,000 tons of fungicides and 37,000 tons of fungicides were sold 
worldwide and in the United States, respectively [7]. Similarly, therapeutic antifungal 
agents are also used either topically or systemically to treat mycoses in humans. These 
antifungals have revolutionized the treatment options of fungal infections in medicine. In 
2011, the estimation of the global market for antifungal therapeutics was valued at $10.7 
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billion and is expected to reach $12.2 billion in 2016. In 2011, the market for antifungal 
therapeutics in U.S. alone was valued nearly $4.5 billion and is expected to total nearly 
$4.9 billion in 2016. 
Moreover, fungi are complex organisms that share many biochemical targets with 
other eukaryotic cells. Due to this reason, the development of new antifungal agents 
remains a major challenge. Although antifungal agents have been pursued for decades, 
there are limited numbers of effective drugs available to fight against invasive fungal 
infections. Concerns with inconsistent and declining effectiveness due to resistance, 
environmental impacts, animal and human toxicity and costs continue to challenge their 
use. Thus, there is a serious need for the development of new antimicrobials that are more 
effective, eco-friendly, less toxic and have low incidences of fungal resistance. 
Antifungal agents in medicine 
Over the years, a number of antifungal agents have been discovered and assessed 
for use in the treatment of systemic mycoses. Among them, the polyenes, imidazoles, 
triazoles, allylamines, griseofulvin, and 5-fluorocytosine have proved to be most useful 
antifungal agents. These drugs can be divided into four broad groups on the basis of their 
molecular mechanism of action. These antifungal agents either inhibit ergosterol 
synthesis, impair membrane barrier function, interact with microtubules or inhibit 
macromolecule synthesis.  
Polyenes 
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Over the past few decades, polyene antifungals have been important for the 
treatment of invasive fungal infections in medicine. Amphotericin B, nystatin, and 
natamycin represent the polyene class of antifungal agents. Among them, amphotericin B 
is the only polyene antibiotic that has been successfully developed as a systemic 
antifungal agent against systemic mycoses. Amphotericin B is a broad-spectrum 
antifungal agent produced by Streptomyces nodosus [8] that exerts its antifungal activities 
by binding preferentially to ergosterol in the fungal cell membrane, as compared to 
cholesterol in the human plasma cell membrane. It destabilizes the fungal plasma 
membrane by pore formation leading to the leakage of intracellular components such as 
K+ ions and eventually cell death [9]. Amphotericin B still remains a gold standard for 
the treatment of invasive fungal infections. However, the use of amphotericin B is limited 
by its inherent toxicity [10]. 
Pyrimidines 
5 flurocytosine (5-FC) and 5-flurouracil (5-FU) are two pyrimidines that are 
synthetic structural analogs of DNA nucleotide cytosine. 5-FC was synthesized in 1957 
by Duschinsky et al. 1960, initially as an antitumor agent, but later discovered for its 
antifungal potential to treat fungal infections such as crytococcosis and candidiasis [11, 
12]. It also exerts broad spectrum antifungal activities against Candida, Cryptococcus 
and Aspergillus species. 5-FC enters the fungal cell through active transport on ATPases. 
It is then converted to active 5-fluorouracil (5-FC) by fungal cytosine deaminase to active 
5-fluorouracil (5-FU) which is incorporated into RNA causing faulty RNA synthesis. 
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However, monotherapy with 5-FC is not advisable because it is thought to promote the 
development of fungal resistance. But it has been effectively used in combination with 
amphotericin B or azoles [13]. 
Azoles 
Azoles are by far most widely used antifungals in clinical practice as well as in 
agriculture. They are also the most widely studied antifungal agents regarding their mode 
of action, pharmacological properties and mechanism of resistance. There are two classes 
of azoles, imidazole and triazoles. Benzimadazole were the first imidazole discovered by 
Wooly (1944) as an antifungal agent [14]. Many other agricultural and medical azoles 
were subsequently developed based upon the azole ring.  
Triazoles, a subset of the azole drugs, were developed in the 1980s and 1990s and 
that have wide spectrum of activity and also an excellent safety profile [15]. Azoles exert 
inhibitory effects on fungi by inhibiting the enzyme lanosterol-14-alpha- demethylase, 
which is responsible for converting lanosterol to ergosterol (a necessary fungal cell 
membrane component). Loss of ergosterol production increases the cell membrane 
permeability, leading to cell death [16]. A major problem associated with the use of 
azoles is the emergence of resistance, mainly through point mutations affecting the gene 
encoding the target enzyme or by overexpression of drug efflux pumps [17]. However, 
azoles remain a mainstay to treat systemic mycosis in humans, and are widely used in 
agriculture.  
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Echinocandins 
The final and most recently developed class of antifungals, having only been used 
since the new millennium, is the echinocandins which are semisynthetic lipopeptides. 
They act by blocking glucan synthase inhibiting 1,3-β-D-glucan synthesis [18]. 1,3-β-D-
glucan is key structural component of the fungal cell wall that is not present in 
mammalian (host) cells. This makes echinocandins the first class of antifungals that 
target a fungal specific component; thus giving them an excellent safety profile [19]. 
Caspofungin was the first of the echinocandins to be introduced in 2001. Currently there 
are 3 total available echinocandins, namely caspofungin, anidulafungin and micafungin 
approved for human use by the FDA. All of them have a broad spectrum of activity 
against fungi. Despite their recent introduction, there has been a report of resistance to 
these antifungal agents mainly through the mutations in the gene encoding the target 
enzyme glucan synthase [20]. 
Other ergosterol biosynthesis inhibitors  
In addition to azoles, other types of antifungal agents inhibit the ergosterol 
biosynthesis in fungi. The allylamine and thiocarbamates, such as terbinafine and 
tolnaftate, both inhibit the enzyme squalene epioxidase encoded by ERG1 [21]. Likewise, 
the morpholines, such as amorolfine exert inhibitory effects on fungi by inhibiting two 
different enzymes of the biosynthetic pathway, Δ7, 8-isomerase (encoded byERG24) and 
the C14-reductase (encoded byERG2) [22]. Due to their numerous side effects, their 
therapeutic regimens are limited to treat dermatophytosis and onchomycosis. 
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Syringomycin 
Syringomcycins are a family of small cyclic lipodepsinonapeptides that are 
produced as secondary metabolites by the plant bacterium Pseudomonas syringae pv. 
syringae. The best studied, syringomycin E (SRE), exhibits broad-spectrum antifungal 
activities without inhibiting bacteria. It has been reported that SRE tends to be more 
effective against yeast than against filamentous fungi [23]. 
Among these lipodepsinonapeptides, SRE is a broadly investigated peptide in 
terms of its structure and the fungicidal mechanism of action. Due to the presence of 
hydrophobic lipid moiety and the hydrophilic peptide portion, SRE acts as an 
amphipathic molecule with the ability to interact with the fungal plasma membrane as the 
primary site of action [24]. Upon binding to plasma membrane, SRE forms voltage 
dependent pores that facilitate the movement of intracellular ions such as K+ and Ca2+ 
from fungal cells, leading to the cell death [25, 26, 27, and 28]. 
Molecular genetic analysis of yeast strains in response to SRE was conducted that 
allowed identification of the yeast genes necessary for SRE action [29, 30]. The majority 
of genes that are responsible for SRE action are sphingolipid biosynthetic genes such as 
SYR2, FAH1, ELO2, ELO3, CSG1, CSG2, and IPT1.One ergosterol biosynthetic gene, 
SYR1/ERG3, was also found to be involved in SRE action [29, 30, 31].Mutant strains 
lacking function in any one of the above genes showed resistance to SRE whereas wild 
type strain was sensitive to SRE [32]. 
 
8 
 
ANTIFUNGAL DRUG COMBINATION THERAPY 
Antifungal therapies that are currently available show limited clinical efficacy to 
some invasive fungal infections, such as aspergillosis and fusariosis. The problem of 
frequent opportunist fungal infections and the resistance to available antifungal drugs 
promoted researchers to explore new strategies for treatment of fungal infections. Drug 
combination therapy offers unique advantages as the drugs can concurrently target 
different processes to enhance the potency of drug activity, overcome the problem of 
drug resistance, and reduce the effect of drug toxicity [33]. 
When two drugs or agents are combined for treatment, there can be three types of 
interaction between drugs or agents: synergistic, indifference and antagonistic. 
Synergistic interaction means that the effect of two chemicals taken together is greater 
than the sum of their separate effects at the same doses. Indifference interaction means 
the combined effect of two chemicals is simply the effect of the most active drug alone. 
Antagonistic interaction means that the combined effect of two chemicals is less than 
when two drugs are tested separately. 
During past decades, several drug combinations that have been tested in vitro and 
in vivo have shown greater effectiveness in combination to treat invasive fungal 
infections compared to each drug alone. For example, amphotericin B acts synergistically 
with fluorocytosine to treat candidiasis both in vitro and in vivo [34, 35]. No synergy was 
observed between amphotericin B and fluconazole in vitro, but interestingly, in animal 
models this combination has been associated with improved survival rates and decreased 
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tissue burden of C. albicans [36, 37, 38]. It has been reported that the success rate of 
treating candidaemia with fluconazole-amphotericin B combination was 69% in 
combination therapy compared to 59% for those receiving monotherapy [39].Similarly, 
azole-terbinafine combinations seem promising in vitro and in animal models [40]. 
Fluconazole acts synergistically with cyclosporine to reduce yeast burden in kidneys 
compared to the results seen with either agent alone in a rat model of endocarditis [41]. 
Similarly, amphotericin B-fluorocytosine combination therapy against Candida prosthetic 
hip infections [42] and meningitis [43, 44] were found to be very effective and 
successful. However, fluconazole- echinocandin combinations have not been successful 
in vitro. Combinations of fluconazole with antibacterial agents such asciprofloxacin and 
trovafloxacin raised survival rates of mice in a model of systemic candidiasis [45]. 
Although investigation of antifungal drug combinations is still in the early stages, 
there have been documented examples of success of combination therapy improving 
survival rates in animal models against various fungal infections. Drug combination 
therapy may lead to the discovery of new clinically applicable antimicrobial therapies. 
AMINOGLYCOSIDES 
Aminoglycosides are highly potent, broad spectrum antibiotics that are used as 
therapeutics mostly to treat serious bacterial infections such as septicaemia, nosocomial 
respiratiory tract infections, urinary tract infections (UTIs) and intra-abdominal infections 
caused by aerobic Gram negative bacilli in humans [46]. Aminoglycosides such as 
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streptomycin and gentamicin are also used to treat bacterial diseases in plants, such as the 
fire blight of apples and pears caused by species of Erwinia, Pseudomonas, and 
Xanthomonas [47]. Most of the amingolycosides are naturally occurring antibiotics and 
are readily produced by actinomycetes of either genus Streptomyces or Micromonospora 
[48]. The era of aminoglycoside antibiotic therapy was initiated with the discovery of 
first antituberculosis agent, streptomycin, by Waksman in 1944. Since then a series of 
aminoglycosides including neomycin (1949), kanamycin(1957), paromomycin (1959), 
gentamicin (1963), tobramycin (1967), sisomicin (1970), butirosin (1971), lividomycin 
(1971),and others have been discovered and introduced to treat bacterial infections 
caused by Gram-negative and Gram-positive bacteria [49, 50]. 
Aminoglycosidemode of action 
Aminoglycosides are hydrophilic sugars that consist of several amino and 
hydroxyl functionalities. They are also considered polycationic compounds as the amine 
moieties are mostly protonated at biologically significant pH. They show high affinities 
for RNAs, especially the prokaryotic rRNA [51, 52, 53] where they primarily bind to the 
aminoacyl site (A-site) of the 16S ribosomal RNA (rRNA) within the 30S ribosomal 
subunit of bacteria, inducing misreading of the genetic code and production of aberrant 
proteins [51]. Aberrant proteins may be inserted into the cell membrane, leading to the 
loss of membrane integrity and increased permeability for antibiotics [52]. As a result, 
aminoglycosides accumulate rapidly in the cytoplasm and saturate all ribosomes, 
resulting in cell death.  
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A majority of aminoglycosides are composed of 2-deoxystraptmaine (2-DOS) 
which are decorated by aminosugars at the C4, C5, and C6 positions. The 2-DOS moiety 
plays a critical role in the biological function of this class of antibiotics and has been 
shown to interact directly with the 16S ribosomal RNA [51, 53].Kanamycins represent 4, 
6 disubstituted 2-DOS-containing aminoglycosides that contain two aminosugars such as 
neosamine and kanasomine attached at 4- and 6-postions of the DOS ring 
respectively(Figure 1-1).They are one of the most commercially successful 
aminoglycoside antibiotics, produced by Streptomyces kanamyceticus against bacteria 
[54]. 
Despite being potent antibiotics, aminoglycosides were found to cause nephro- 
and ototoxic reactions in humans, affecting on an average 8-30% of treated patients [55]. 
There are also growing resistant against aminoglycosides that has been detected among 
bacterial species such as methicillin-resistant Staphylococcus aureus (MRSA). The major 
mechanism of aminoglycoside resistance by bacteria is due to enzymatic modification of 
the amino or the hydroxyl groups of these antibiotics by aminoglycoside-modifying 
enzymes (AMEs) such as aminoglycoside acetyltransferase, aminoglycoside 
phosphotransferase, aminoglycoside adenyltransferase in the bacterial periplasma. There 
are more than 50 aminoglycoside deactivating enzymes known today [56, 57]. Although 
this has limited their uses as therapeutics, aminoglycosides still remain valuable drugs for 
the treatment of infections and for prophylaxis in special situations.  
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Thus, there is still a huge motivation to synthesize novel derivatives from 
aminoglycosides either to improve their efficacy or to seek new applications. This 
strategy has resulted in the development of new effective semisynthetic aminoglycoside 
derivatives, such as netilmicin, amikacin, and isepamicin [58, 59, 60]. In the past, efforts 
have also been made to design novel aminoglycosides that induce a dual action towards 
both protein synthesis and bacterial membranes. The latter are targeted by the addition of 
lipophilic tails [61], linear lipidic acyl groups [62, 63] and lipid chains, 
polyguanidinylated head groups [64], or hydrophobic residues in the form of 
polycarbamate and polyethers [65] to the backbone of aminoglycoside. All the 
synthesized derivatives have exhibited a strong activity against Gram-positive bacteria, 
including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
enterococci (VRE), but they have failed to show activity against Gram-negative bacteria 
[61, 62]. However, Ouberai et al. (2011) showed that the novel aminoglycoside 
naphthylmethylneamine derivatives inhibit the gram negative bacterium P. aeruginosa by 
targeting its cell membrane [66]. But for the first time, Chang et al.2010 showed a novel 
neamine aminoglycoside analog, FG08—with a linear C8 alkyl chain as a major 
structural feature—is antifungal, in contrast to its prototype analog kanamycin B that is 
predominantly antibacterial. This strategy is an example of reviving a clinically important 
aminoglycosideby simple chemical modification to yield a new application [67]. 
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Aminoglycosides as antifungal agents 
The aminoglycosides are predominantly antibacterial. However, it has been 
reported that some aminoglycosides, such as validamycins are useful as a crop protectant 
against plant pathogenic fungi that attack roots and are also effective in protecting 
seedling and clone cuttings against fungal damping-off disease [68].It has been noted that 
some unusual bicyclic ring-containing aminoglycosides are active against yeasts [69]. 
Additionally, a recent report revealed inhibition of plant pathogenic oomycetes 
Phytophora spp. And Pythium spp. by neomycin, paramomycin, ribostamycin and 
streptomycin, although they showed comparatively little activity against several other 
fungal genera [70]. The exact mode of action of these aminoglycosides against fungi is 
still unknown. Recently, FG08 and K20, both novel aminoglycosides, have been reported 
to inhibit fungi but not bacteria. FG08 and K20 differ from most aminoglycosides by the 
addition of a C8 alkyl chain. FG08 and K20 appear to act by the disrupting fungal cell 
membrane but it is not clearly understood whether FG08 effects on membranes are direct 
or indirect [67]. Like syringomycin E, the amphipathic properties of these novel 
aminoglycosides may promote their interaction with the plasma membrane as a primary 
site of action. 
Although potentially useful as crop protectants, the application of currently 
available aminoglycosides to prevent crop diseases is not advisable as such practices are 
anticipated to cause bacterial resistance to medicinally used antibiotics. It would be 
desirable to have a new antimicrobial agent that shows selective activity against either 
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bacteria or fungi so the treatment for one of either bacterial or fungal diseases does not 
promote the development of antimicrobial resistance in the other. Thus, the best 
aminoglycoside-based fungicides could be those like FG08 or K20 that show potent 
fungicidal activities, but completely lack their antibacterial capabilities. 
JUSTIFICATION AND OBJECTIVES FOR THE PRESENT RESEARCH 
Invasive fungal infections are on the rise as the number of patients with 
compromised immune systems continues to increase. Crops are threatened by emerging 
fungal diseases that pose serious threats to crop health and to the entire agriculture 
industry. Currently, there are few classes of antifungal agents available to fight against 
fungal infections in medicine and agriculture. These antifungal agents have a narrow 
spectrum of molecular targets. The therapeutic regimens of current antifungal agents are 
far from satisfactory and many fungi are evolving resistance to current antifungal agents. 
Further, declining efficacy of current antifungals due to resistance, concerns with animal 
and human toxicity, environmental impacts and costs also continue to challenge their 
uses as therapeutics. Thus, discovery of novel antifungals that exhibit broad-spectrum 
activities, selective toxicity, low incidences of resistance, and varied mechanisms of 
action is warranted. Some strategies, such as modifying the chemical structure of existing 
antibiotics or exploring the synergistic combination of two or more agents, may lead to 
the discovery of additional antimicrobials for therapies.  
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The overall goal of this research is to investigate the bioactive properties of novel 
aminoglycoside analogs, FG08 and K20—their bioactive properties, mechanism of 
action, and synergistic interactions with therapeutic antifungal azoles. FG08 and K20 are 
derived from kanamycin B and kanamycin A, respectively. They exhibit promising 
antifungal activities without inhibition of bacteria. As the spectrum of one antimicrobial 
can vary largely from others, it is essential to explore the bioactivity spectrum of these 
analogs for their specificity. For example, fungi share many biochemical targets with 
eukaryotic cells, so agents that interact with fungal targets may also attack similar targets 
present in animals and plants, making them unsuitable for treating fungal infections. As 
the fungicidal mechanism of action of these compounds is likely to be unique among 
aminoglycosides, studies of the fungicidal inhibitory action of these analogs are of major 
interest. Azoles are currently commercially available and widely used antifungal agents 
to treat fungal infections in agriculture and medicine. Since azoles are fungistatic, they 
may more likely lead to the development of fungal resistance. One of the possible 
strategies to prevent this problem is by using combination therapy. If synergy is observed 
between K20 and azoles, today’s most widely used antifungal agents, it could have broad 
and important implications in agriculture and medicine to combat important fungal 
diseases. In the present study, the bioactive properties, mechanism of action of FG08 and 
K20, and their synergistic antifungal interactions with azoles were studied. 
In addition to this, chemoenzymatic synthesis of novel aminoglycoside analog, 
FG08 (Appendix A), the effect of K20 on the dimorphic transition of C. albicans 
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(Appendix B), and bioactivity of novel aminoglycoside, FG03 (Appendix C) were 
studied. 
The main objectives of this research were: 
1) To evaluate the antimicrobial spectrum of FG08 and K20 against fungi and 
bacteria, 
2) To determine the hemolytic and cytotoxicity effects of FG08,and K20 on 
mammalian cells in vitro, 
3) To investigate the fungicidal mechanisms of action of these analogs, and 
4) To explore the synergistic interaction of K20 with therapeutic antifungal 
azoles. 
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CHAPTER 2 
MEMBRANE LIPID-MODULATED MECHANISM OF ACTION AND NON-
CYTOTOXICITY OF NOVEL FUNGICIDE AMINOGLYCOSIDE FG08 
 ABSTRACT  
A novel aminoglycoside, FG08, derived from kanamycin B by substitution of a 
C8 alkyl chain at the 4″-O position, was previously reported. Unlike kanamycin B, FG08 
shows broad-spectrum fungicidal but not anti-bacterial activities. To understand its 
specificity for fungi, the mechanism of action of FG08 was studied using intact cells of 
the yeast Saccharomyces cerevisiae and small unilamellar membrane vesicles. With 
exposure to FG08 (30 µg mL-1), 8-fold more cells were stained with fluorescein 
isothiocyanate, cells had 4- to 6- fold higher K+ efflux rates, and 18-fold more cells were 
stained with SYTOX Green in comparison to exposure to kanamycin B (30 µg mL-1). 
Yeast mutants with aberrant membrane sphingolipids (no sphingoid base C4 hydroxyl 
group, truncated very long fatty acid chain, or lacking the terminal phosphorylinositol 
group of mannosyl-diinositolphosphorylphytoceramide) were 4 to 8-fold less susceptible 
to growth inhibition with FG08 and showed 2 to 10-fold lower SYTOX Green dye uptake 
rates than did the isogenic wild-type strain. FG08 caused leakage of pre-loaded calcein 
from 50% of small unilamellar vesicles with glycerophospholipid and sterol compositions 
that mimic the compositions of fungal plasma membranes. Less than 5 and 10% of 
vesicles with glycerophospholipid and sterol compositions that mimic bacterial and 
mammalian cell plasma membranes, respectively, showed calcein leakage. In tetrazolium 
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dye cytotoxicity tests, mammalian cell lines NIH3T3 and C8161.9 showed FG08 toxicity 
at concentrations that were 10 to 20-fold higher than fungicidal minimal inhibitory 
concentrations. It is concluded that FG08’s growth inhibitory specificity for fungi lies in 
plasma membrane permeability changes involving mechanisms that are modulated by 
membrane lipid composition. 
INTRODUCTION 
Aminoglycosides are compounds having two or more amino sugars bound to an 
aminoacyclitol ring via glycosidic bonds. Many are used therapeutically against bacterial 
infections of humans and animals. Among them, kanamycin B (Figure 2-1), produced by 
the soil microbe Streptomyces kanamyceticus, is one of the most successful [1, 2, 3]. 
Kanamycin B is structurally based on sugar rings I and II of neamine with an attached 
ring III of O-6-linked kanosamine. The aminoglycosides are generally viewed to act 
against bacteria [3]. Most bind directly to the prokaryotic 16S rRNA in the decoding 
region A site, leading to the formation of defective cell proteins. Despite being mainly 
antibacterial, certain classical aminoglycosides are also found to inhibit crop pathogenic 
fungal oomycetes [4], and certain structurally unusual ones inhibit yeasts and protozoans 
[5, 6]. 
Recently, we reported a novel aminoglycoside, FG08 (Figure 1), with broad 
spectrum fungicidal activity [7]. FG08 is derived from kanamycin B by substitution of a 
C8 alkyl chain at the 4”-O position of ring III. It, however, lacks the antibacterial 
properties characteristic of kanamycin B and is fungicidal to a variety of yeasts, 
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oomycetes, and true fungi with in vitro minimal inhibitory concentrations (MICs) ranging 
between 3.9 and 31.3 µg mL-1 [7]. The addition, the C8 alkyl chain, imparts an 
amphipathic character that suggests the possibility for interaction with cell membranes. 
Increased SYTOX Green dye uptake by FG08-treated Fusarium graminearum and 
Candida albicans indicate effects on the plasma membrane [7]. As a consequence, among 
antimicrobial aminoglycosides, FG08 appears to interact preferentially with membranes 
rather than ribosomes. What follows are questions about the mechanism of action on 
membranes and whether such a mechanism accounts for the fungicidal effects. To 
address these questions, it is important to determine FG08’s initial molecular target, e.g. 
lipid or protein or both. FG08’s structure, composed of a hydroxyl and multiple amino 
groups, suggests possible interactions with lipids or proteins with high-densities of 
hydrogen and ionic bonding sites exposed on the membrane external surface. Also, the 
molecular target(s) will need to account for FG08’s preferential inhibition of fungi over 
bacteria and mammalian cells.  
In this study, we investigated FG08’s fungicidal mechanism of action on the 
plasma membrane of the yeast S. cerevisiae. We employed membrane-impermeable 
fluorescence-capable dyes and the cellular efflux of K+ to measure FG08 membrane pore-
forming capabilities. Comparisons between wild-type and gene deletion mutants with 
structural or compositional defects in anionic sphingolipids were investigated to 
determine the influence of these lipids in FG08 action. Small unilamellar vesicles (SUVs) 
with glycerophospholipid and sterol compositions that mimic the lipid compositions of 
fungal, bacterial and mammalian cell plasma membranes were examined to determine the 
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influence of these lipids on FG08 membrane interaction and specificity. Finally, the cell 
permeability and cytotoxic effects of FG08 on mammalian cells were evaluated. The 
results suggest that FG08’s fungicidal mechanism of action involves interaction with and 
perturbation of the fungal plasma membrane and that its specificity for fungal vs. 
mammalian and bacterial cells is influenced by membrane lipid composition. 
MATERIALS AND METHODS 
FG08  
FG08 was synthesized from kanamycin B as previously described [7]. A 10 mg 
mL-1 stock solution was prepared in twice distilled water and stored at 5oC. 
Yeast strains and growth medium 
S. cerevisiae strains used in this study were W303C (MATa ade2 his3 leu2 trp1 
ura3) and isogenic sphingolipid biosynthesis mutant strains W303-∆syr2 (MATα ade2 
his3 leu2 trp1 ura3 syr2 (sur2)::URA3), W303-∆elo2 (MATα ade2 his3 leu2 trp1 ura3 
elo2::HIS3), W303-∆elo3 (MATα ade2 his3 leu2 trp1 ura3 elo2::HIS3),and W303-∆syr4 
(ipt1) (MATαade2 his3 leu2 trp1 ura3 syr4 (ipt1)::URA3 [8,9]. The mutants are single 
gene disruptants isogenic with parental strain W303C. They all have defective 
sphingolipids that either lack the C4-hydroxyl group of the phytosphingosine backbone 
(W303-∆syr2), have truncated very long fatty acyl chains (W303-∆elo2 and W303-
∆elo3), or, because of the inability to add a terminal phosphoinositol group to MIPC, lack 
the most complex and abundant yeast sphingolipid, mannosyl-
diinositolphosphorylphytoceramide (MIP2C) (W303-∆syr4 (ipt1). Phenotypically, these 
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mutants lack sensitivity to the antifungal syringomycin E - a membrane lipidic pore 
forming cyclic lipodespsipeptide [9]. Yeast cells were grown in YPD medium (1% yeast 
extract, 2% peptone, and 2% glucose).  
Fluorescent dye staining  
Yeast cells were grown for 18 h in YPD medium, and the cell density was 
adjusted to 1 x 107 cells mL-1.  Aliquots (500 µL) were taken and centrifuged for 2 min at 
10,000g. The cell pellet was suspended in 10 mM HEPES, pH 7.4, centrifuged again, and 
suspended in 500 µL of distilled water [7]. For fluorescein isothiocyanate (FITC) 
staining, FG08 was added to 100 μL of the cell suspension to give final FG08 
concentrations of 30, 62.5 and 125 μg mL-1 (1, 2 and 4x the FG08 MIC, respectively) and 
incubated for 1 h at 28oC with continuous agitation. The cell suspensions were mixed 
with 6µg mL-1 FITC (Sigma Aldrich) (10 mg mL-1 stock solution in acetone) for 10 min 
following published procedures [10]. At least 400 imaged cells were scored for 
fluorescence per experiment. Staining with the cationic and fluorescent nucleic acid 
binding dye SYTOX Green (Molecular Probes) was performed as previously described 
[7, 11]. SYTOX Green was added (final concentration, 0.2 µM) to 100 μL of yeast cell 
suspensions and allowed to stand for 10 min before addition of FG08 (30 μg mL-1) or 
kanamycin B (30 μg mL-1). Negative (water) and positive (Triton X-100®, 1%, vol vol-1) 
treatment controls were also prepared. Glass slides were prepared with 10 μL of each cell 
suspension-FITC or SYTOX Green mixture and observed in bright field and fluorescence 
modes using an Olympus IX81 fluorescence microscope and an Olympus MWIB filter 
with excitation and emission wavelengths of 488 and 512 nm, respectively. Images and 
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data were obtained from at least two independent experiments each performed in 
duplicate. The percentages of stained cells were determined by comparing paired bright-
field and fluorescence images.  
K+ efflux 
Previously described K+ efflux measurement methods [12] were used with 
modification. An overnight culture of S. cerevisiae W303C grown in YPD medium was 
centrifuged at 1200 g for 5 min at room temperature. The cell pellet was washed twice 
with sterile deionized water. After the second wash step, the cells were suspended in 
sterile 10mM HEPES-NaOH buffer, pH 6.5 with 25 mM glucose. Washed cells were 
used to inoculate 10 mL of sterile buffer solution to make final cell density of 1 x 
107 CFU mL-1 in a sterile 50mL capacity polyethylene tube (Corning). The cell 
suspension was incubated with 30 µg mL-1 of FG08 for 1.0, 5.0, 10, 20 and 60 min in a 
MaxQ 6000 incubator (Thermo Fisher Scientific) at 300C with agitation at 200 rpm. Cell-
free filtrates were obtained by individually filtering each suspension with syringe filters 
(0.2 µm, Nalgene). The filtrates were subjected to atomic emission spectrometry using a 
Varian AA240 FS atomic absorption spectrometer at 766.5 nm to determine the 
extracellular K+ concentrations using a standard calibration curve based on KCl solutions. 
Boiled (20 min) cell suspensions were used to estimate total cellular K+. Untreated cells 
were used as negative controls. K+ efflux was calculated as percentage of total cellular 
K+ using the formula: K+ efflux (%) = ((extracellular K+ –extracellular K+ in negative 
control)/ (total cellular K+)) x 100. 
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Calcein release from small unilamellar vesicles (SUVs)  
Phosphatidylcholine (PC) from Glycine max, L-α-phosphatidylethanolamine (PE) 
from Escherichia coli, L-α-phosphatidylglycerol (PG) (sodium salt) from egg yolk 
lecithin, L-α- phosphatidylinositol (PI) (sodium salt) from G. max, ergosterol and 
cholesterol were purchased from Sigma-Aldrich. SUVs were prepared by dissolving the 
lipids (either singly or as mixtures) in chloroform/methanol (2:1, by vol). The mixtures 
were PC, PE, PI and ergosterol (5:4:1:2 by wt), PC and PG (7:3 by wt), and PC and 
cholesterol (10:1 by wt) that mimic the lipid compositions of fungal [11], bacterial [13], 
and mammalian cell plasma membranes, respectively [11]. The organic solvent was 
evaporated under a stream of nitrogen and the lipid mixture was allowed to dry under 
vacuum overnight. The dried lipid films were rehydrated in HEPES buffer (10 mM 
HEPES, 150 mM NaCl, pH 7.4) and 60 mM calcein (self-quenching concentration) and 
the suspensions were sonicated for 5 min using a bath sonicator (SonicatorTM Heat 
System, W-220F, Ultrasonic, Inc.) to generate SUVs with lipid concentrations at 10 mg 
mL-1 [14].The free calcein was removed by gel filtration through a Sephadex G-50 
column. FG08 at 5, 20, and 50 µg mL-1 were added to the calcein-loaded SUV 
suspensions (FG08:lipid molar ratios of 1.5:1, 6:1, and 14.5:1, respectively) and calcein 
leakage was followed by measuring fluorescence using a Synergy HT microplate reader 
at an excitation wavelength of 488 nm and emission wavelength of 520 nm. Complete 
(100%) dye release was obtained by addition of 1% (vol vol-1) Triton X100®. The dye-
leakage percentage was calculated as: %dye leakage=100×(F−F0)/(Ft−F0), where F 
represents the fluorescence intensity 2 min after FG08 addition, and F0 and Ft represent 
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the fluorescence intensity without FG08 and with 1% (vol vol-1) Triton X-100®, 
respectively [14]. 
FG08 susceptibility testing of wild type and sphingolipid biosynthesis mutants 
Microbroth dilution assays for determination of minimal inhibitory concentrations 
(MICs) were conducted using the protocols of the Clinical and Laboratory Standards 
Institute [15]. Yeast inocula were adjusted to a final concentration of 5 × 105 CFU mL-1. 
Drug dilutions were prepared in YPD medium broth ranging between 0.97 and 250 µg 
mL-1. For disk diffusion growth inhibitory assays, cultures were spread on YPD medium 
agar plate surfaces. Paper disks (0.5 cm diameter) were placed on the surfaces, and 10 µL 
aliquots of 1 mg mL-1 of FG08 solution was applied to the disks. Clear zones of 
inhibition were observed after incubation at 28o C for 48 h. Each test was performed in 
triplicate. 
Animal cell cytotoxicity 
A C8161.9 melanoma cell line was a gift from Dr. Danny R. Welch, University of 
Kansas, Lawrence, KS (USA). The cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM)/Ham’s F12 (1:1) containing 10% fetal bovine serum [16]. NIH3T3 
cells (ATCC® CRL-1658™, American Type Culture Collection, Manassas, VA, USA.) 
were grown in DMEM (high glucose) media containing 10%, vol vol-1 fetal bovine serum 
in Corning Cell Bind flasks. The confluent cells were then trypsinized with 0.25% wt vol-
1 trypsin and resuspended in fresh medium (DMEM). The cells were transferred into 96-
well plates at a density of 2 x 105 cells mL-1. They were mixed with FG08 at final 
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concentrations of 10, 20, 50, 100 or 250 µg mL-1 or an equivalent volume of sterile 
double distilled water (negative control). The cells were incubated for 24 h at 37O C with 
5% CO2 in a humidified incubator.  To evaluate cell survival each well was treated with 
10 µL of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) (Sigma-
Aldrich) for 4 h. In living cells, mitochondrial reductases convert the MTT tetrazolium to 
formazan which precipitates. Formazan was dissolved using acidified NaDodSO4 (10 
mM HCl) and quantified at A570 using a Synergy 4 Gen 5 spectrophotometer (BioTek). 
Triton X-100® (1%, vol vol-1) gave complete loss of cell viability and was used as the 
positive control. Percent cell survival was calculated as: (control value – test value) × 
100/control value, where control value represents cells + MTT – drug, and test value 
represents cells + MTT + drug.  
RESULTS 
Fluorescent dye uptake and K+ efflux by S. cerevisiae strain W303C 
With exposure to FG08 at its MIC (30 µg mL-1), 40% of the strain W303C cells 
were stained with FITC. In contrast, 8-fold fewer cells (5%) were stained when exposed 
to kanamycin B (30 µg mL-1). Unexposed cells were negligibly stained (2%) (Figure 2-2, 
1A- C). The FG08 effect was dose-dependent with complete (100%) staining achieved 
with 125 µg mL-1 (Figure 2-2, D1). 
Seventy percent of the cells of strain W303C in suspension showed accumulation 
of SYTOX Green after a 10 min exposure to FG08 at 30 µg mL-1(Figure 2-3, A1-A2).  
Six percent of cells were stained by SYTOX Green after exposure to kanamycin B (30 µg 
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mL-1) (data not shown). When observed by phase contrast microscopy and in the absence 
of fluorescent dye, intact cells exposed for 10 min to FG08 (30 µg mL-1) showed granular 
cytoplasmic contents not seen with untreated cells (Figure. 2-4).  
Increased K+ efflux by yeast cells is observed with plasma membrane perturbation 
by pore forming agents [12, 13]. A rapid (half-maximum rate < 1 min) efflux of K+ was 
observed when strain W303C cells were exposed to FG08 at 20 to 100 µg mL-1 
concentrations (Figure 2-5). Extracellular K+ levels approached 90% (within 5 min) of 
the maximum (100%) level achieved with Triton X-100® (1%, vol vol-1). Exposure to 
kanamycin B (50 µg mL-1) caused rapid efflux up to 20% of maximum level, whereas 
untreated cells reached 10% of maximum level.  
FG08-dependent calcein release by SUVs  
In order to correlate FG08’s membrane perturbation  effects  and its selective 
killing of fungi, calcein-loaded SUV model membranes representing fungal, bacterial and 
mammalian cell membranes were prepared and evaluated [11,13].  Within 30 min, FG08 
(30 µg mL-1) caused 50% calcein leakage from SUVs containing a mixture of PC, PE, PI, 
and ergosterol (5:4:1:2 by wt) (Figure 2-6). In contrast, at the same concentration of 
FG08, > 10 % leakage was observed from SUVs with PC and PG (7:3 by wt) and with 
PC and cholesterol (10:1 by wt) (Figure 2-6).SUV suspensions without added FG08 
showed less than 2% leakage even after 2 h incubation.  
 
 
37 
 
FG08 susceptibility of mutants with sphingolipid biosynthesis defects 
To determine the influence of sphingolipids on FG08’s fungicidal activity, 
isogenic yeast mutant strains W303-Δsyr2, W303-Δelo2 and W303-Δelo3 and W303-
∆syr4 (ipt1) with sphingolipid structural defects [8, 9] were examined. Strains W303-
Δsyr2, W303-Δelo2, W303-Δelo3 and W303-∆syr4 (ipt1) were all less susceptible to 
growth inhibition by FG08 compared to the isogenic wild-type strain W303C (Figure 2-
7) with MICs that were 4 to 8-fold higher than for strain W303C (Table 2-1).  With 10 
min exposure to FG08 (30 µg mL-1), SYTOX Green stained 35%, 7%, 9.4% and 6.8% of 
the cells of strains W303-Δsyr2, W303-Δelo3,W303-Δelo2, and (W303-∆syr4 (ipt1), 
respectively, as compared to 70% of the strain W303C cells (Figure 2-3).  
Animal cell cytotoxicity 
FG08 concentrations needed to kill C8161.9 and NIH3T3 cells exceeded or 
equaled 250 µg mL-1, respectively (Figure 2-8). This is 10-20 fold higher than the 
antifungal MICs against wild type S. cerevisiae strain W303C. The membrane 
permeabilizing effect of FG08 was also measured on C6181.9 cells. Unlike its effect on 
S. cerevisiae, treatment of C6181.9 cells with 100 µg mL-1 of FG08 caused no influx of 
SYTOX Green dye over 30 min (Figure 2-9). 
DISCUSSION 
Multiple approaches were used to assess membrane-perturbation effects of FG08 
on the yeast plasma membrane. The dye FITC traverses the cell surface if the plasma 
membrane is damaged or permeabilized by external agents and concentrates 
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intracellularly to impart green fluorescence [10]. Similarly SYTOX Green does not cross 
the plasma membrane of intact yeast cells unless its permeability is compromised [7, 11]. 
At antifungal MICs, FG08 elicited dye uptake by both FITC and SYTOX Green by strain 
W303C cells within 10 min and was12-foldmore effective than kanamycin B.  Similar 
FG08 effects on SYTOX Green dye uptake by Fusarium graminearum and Candida 
albicans were previously observed [7]. In addition, rapid (< 5min) and massive (~95% of 
controls) effluxes of K+ with FG08 exposure suggest FG08 pore formation on the yeast 
plasma membrane. Finally, yeast cells showed granular cytoplasmic contents within 10 
min of FG08 treatment with phase contrast microscopy (Figure. 2-4). The combined 
observations indicate that FG08’s quick growth inhibitory effects are caused by 
membrane-perturbation effects that compromise normal ion and metabolite gradients 
across the cell surface. 
To examine the influence of lipids on FG08 membrane perturbation effects and 
FG08’s inhibitory preference for fungi, calcein leakage studies were conducted with 
model membrane SUVs. SUVs were produced with glycerophospholipid and sterol 
compositions that mimic those of fungal (PC, PE, PI, and ergosterol), bacterial (PC and 
PG), and mammalian (PC and cholesterol) plasma membranes [11, 13]. FG08 caused ~5 
fold more calcein leakage with fungal plasma membrane-mimicking SUVs than with 
bacterial and mammalian plasma membrane-mimicking SUVs. These results further 
indicate the membrane perturbing action of FG08. They additionally suggest an influence 
of lipid composition on FG08 action that in turn contributes to FG08’s growth inhibitory 
preference for fungi and yeasts. Compared to FG08’s MICs that inhibit yeast growth, 
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however, about 2 times higher concentrations and longer incubation times (30 min) were 
needed to cause 80% leakage of calcein from fungal mimicking SUVs (Table 2-1 and 
Figure 2-6). These observations indicate that the studied SUV glycerophospholipid and 
sterol compositions influence but by themselves do not account for all of FG08’s yeast 
growth inhibitory capabilities. Other factors including other lipids (e.g. sphingolipids, see 
below) or membrane components likely contribute.  In addition, non-membrane cell 
components that facilitate membrane perturbation could have roles. For example, the 
antifungal action of the plant defensin NaD1 involves a specific interaction with the 
fungal cell wall, followed by membrane permeabilization [17]. 
Unique phosphorylinositol-containing sphingolipids occur predominantly in the 
yeast plasma membrane [18]. The 3 major yeast sphingolipids are inositol-
phosphorylphytoceramide (IPC), mannosyl-inositol-phosphorylphytoceramide (MIPC), 
and M(IP)2C with the latter two biosynthetically made by the sequential addition of 
mannosyl and phosphoinositol groups to IPC. All three sphingolipids possess high 
densities of hydrogen and ionic bonding sites for potential interaction with FG08. To 
determine possible influences of sphingolipids on yeast growth inhibition by FG08, 
biosynthetic mutants with aberrant sphingolipid structures or composition were screened 
against FG08. Strain W303-Δsyr2 produces sphingolipids devoid of the phytosphingosine 
base C4 hydroxyl group. Strain W303-Δelo2 accumulates sphingolipids with truncated 
N-acylated C22 very long fatty acids, whereas sphingolipids of strain W303-Δelo3 are 
devoid of the C26 very long fatty acids. Strain W303-∆syr4 (ipt1) possesses IPC and 
MIPC but lacks M(IP)2C [8,9]. All four mutant strains were less sensitive (4- to 8-fold) 
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to FG08 compared to the isogenic wild-type strain W303C (Figures 2-3 and 2-7) (Table 
2-1). These differences in growth susceptibility to FG08 were further correlated with 
FG08 elicited cell permeability as determined by SYTOX Green uptake (Figure 2-7). 
These results indicate key roles for phosphoinositol sphingolipids in promoting FG08 
action on the yeast plasma membrane. Similar roles for sphingolipids are known for the 
membrane pore-forming antifungal actions of Pseudomonas syringae lipodepsipeptide 
syringomycin E and plant defensin DmAMP1 [19, 20]. 
The influences of lipids on FG08 action could involve hydrogen and ionic 
bonding between FG08 and lipid head groups. FG08 has numerous hydroxyl and amino 
groups, and the yeast glycerophospholipid head groups and sphingolipid C4 hydroxyl and 
mannosyl and phosphorylinositol carbonyl and hydroxyl groups are all potential ionic 
and hydrogen bond donors and acceptors. While elongation of the sphingolipid very long 
fatty acid chain itself does not directly contribute to such interactions, it could do so 
indirectly by affecting the transverse position of the lipid in the membrane and therefore 
membrane surface accessibility of the sphingolipid head groups for bonding. Further 
research is needed to decipher such bonding and molecular interactions that should 
provide more insight into the membrane perturbation effects of FG08 and the reasons for 
the specific targeting of the fungal plasma membrane.  
 In a previous report, FG08 was not hemolytic to sheep erythrocytes even at 
concentrations that exceeded its antifungal MICs [7]. In the present report, we expand the 
descriptions of effects of FG08 on mammalian systems. It is shown that with animal cell 
lines NIH3T3 and C8161.9, FG08 shows low cytotoxicity and minimal membrane 
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perturbation effects at and even above FG08’s antifungal MICs.  Thus, FG08 appears to 
be relatively non-toxic to animals as compared to fungi. 
CONCLUSIONS 
FG08’s growth inhibitory specificity for fungi is suggested to lie in its ability to 
increase plasma membrane permeability by mechanisms that are influenced by the lipid 
composition of the fungal plasma membrane. FG08 has broad-spectrum antifungal 
activities, no antibacterial activity that would promote antibiotic resistance, and low 
mammalian cell toxicities. It thus appears to be a useful lead compound for the 
development of novel antifungal agents. 
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Table 2-1. Growth susceptibilities of yeast sphingolipid biosynthetic mutants to FG08 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain 
 
MIC (µg mL-1) 
W303C (WT) 15.6 - 31.3 
W303-Δsyr2(sur2) >125 
W303-Δelo2 >250 
W303- Δelo3 250 
W303- Δsyr4 (itp1) 250 
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                   Figure 2-1. Structures of aminoglycosides kanamycin B and FG08. 
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Figure 2-2. Membrane perturbation effects of FG08 on intact cells of S. cerevisiae strain 
W303C. FITC dye uptake without (A1, A2) and with FG08 (30 µg mL- 1) (B1, B2) or 
kanamycin B (30 µg mL-1) (C1, C2) exposure for 10 min. Bright-field images (A1, B1 
and C1) are compared with fluorescence images (A2, B2, and C2) to calculate % 
fluorescent cells that are stained with FITC. Image A2 (no FG08 and no kanamycin B) 
shows no fluorescent cells against a fluorescent background. Bar length is 10µm.  Panel 
D1 shows dose-dependent effects of FG08 on FITC dye uptake and effects of kanamycin 
B and no treatment. Triton X-100® (1%, vol vol-1) gave 100% dye influx (data not 
shown). The range bars show variations in % fluorescent cells from analyses of 10 
separate microscopic image fields randomly selected from at least two separate 
experiments. Numbers above the range bars indicate the number of cells analyzed.  
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Figure 2-3. Effect of FG08 on SYTOX Green dye staining of S. cerevisiaestrain W303C 
and isogenic sphingolipid biosynthetic mutants. StrainW303C (A1, A2), and isogenic 
mutants W303-Δsyr2(sur2) (B1, B2), W303-Δelo3 (C1, C2), W303-Δelo2 (D1, D2) 
andW303-Δsyr4 (ipt1) (E1, E2) were exposed to FG08 (30 µg mL-1) for 10 min A) Each 
cell observed in bright-field mode (A1- E1) was also observed for  fluorescence (A2- 
E2), B) The % of fluorescent cells in each microscopic field that stained with SYTOX 
Green was calculated.  The range bars show variations in % fluorescent cells from 
analyses of 10 separate microscopic image fields randomly selected from at least two 
separate experiments. The numbers above the range bars indicate the total number of 
cells analyzed. Untreated yeast cells showed less than 3% staining. Distance bar length 
shows 10 µm. 
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Figure 2-4. Phase contrast microscope images of FG08 effects on the cell internal 
structure of S. cerevisiae strainW303C. Cells were not treated (A) or treated (B) with 
FG08 (30 µg mL-1) for 10 min before visualization by phase contrast microscopy.  
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Figure 2-5. Dose-dependent effect of FG08 on cellular K+ efflux by S. cerevisiae strain 
W303 Cells growing in YPD medium were washed and suspended in 10 mM HEPES-
NaOH buffer, pH 6.5, 25 mM glucose with FG08 at concentrations of 20 (●), 50 (□) or 
100 (▲) µg mL-1 or kanamycin B at 50 µg mL-1 (◊). Controls (×) were not treated with 
FG08 or kanamycin B. Error bars represent data compiled from three separate 
experiments. 
 
 
 
 
 
 
51 
 
 
Figure 2-6. Effect of FG08 on calcein release from SUVs that mimic glycerophospholipid 
and sterol compositions of fungal, bacterial, and mammalian cell plasma membranes. 
Calcein-loaded SUVs made with PC alone (A), or with glycerophospholipid and sterol 
compositions that mimic fungal (PC/PE/PI/ergosterol [5:4:1:2]) (B), bacterial (PC/PG 
[7:3]) (C) or mammalian cell (PC/cholesterol [10:1] (D) plasma membranes [12, 14] were 
exposed to FG08 at 5 (▲), 30 (□), and 62.5 (×) µg mL
-1
, kanamycin B (62.5 µg mL-1) (●) 
and Triton-X 100 (1%) (◊). Error bars represent data compiled from three separate 
experiments. 
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Figure 2-7. Disk-diffusion antifungal assays of FG08 against S. cerevisiae W303C and 
sphingolipid biosynthetic mutants. Ten µL aliquots of 1 mg mL-1 solutions of FG08 were 
applied to paper disks placed on YPD medium agar surfaces spread-plated with YPD 
medium-grown cells of S. cerevisiae strainW303C (A), W303-Δsyr2 (sur2) (B), W303-
Δelo2 (C), W303- Δelo3 (D) and W303- Δsyr4 (itp1) (E). The plates were incubated for 
48 h at 28oC. 
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Figure 2-8. Mammalian cell cytotoxicities of FG08. MTT-based cytotoxicity assays were 
performed with NIH3T3 mouse fibroblast (A) and C8161.9 melanoma (B) cells with 24 h 
exposure to FG08 at various concentrations. The positive control (100% cytotoxicity = no 
cell survival) was provided by treatment with Triton X-100 (1% vol vol-1) (filled bar). 
Error bars represent data combined from three separate experiments. 
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Figure 2-9. Effect of FG08 on SYTOX Green dye staining of C8161.9 cells. Cultured 
C6181.9 cells were exposed to 100 µg mL-1 FG08 and SYTOX Green and viewed 
microscopically in bright-field (A) and fluorescence (B) modes.  Cells treated with Triton 
X-100® (1% vol vol-1) and SYTOX Green was also viewed by bright-field (C) and 
fluorescence (D) microscopy. Bar length is 10 µm. 
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CHAPTER 3 
NOVEL AMINOGLYCOSIDE K20: ANTIFUNGAL PROPERTIES, MECHANISM OF 
ACTION, AND SUPPRESSION OF MURINE PULMONARY CRYPTOCOCCUS 
NEOFORMANS INFECTION 
ABSTRACT 
This study investigated the in vitro antimicrobial activities, cytotoxicity, and 
mechanism of action of K20 and determined its efficacy to suppress pulmonary 
cryptococcosis. 
Antimicrobial susceptibility testing was determined as minimal inhibitory 
concentrations (MICs) using microbroth dilutions assays and with time kill curves. 
Cytotoxicity activities of K20 were evaluated using sheep erythrocytes and mammalian 
cell lines. Mechanisms of action of K20 were studied using intact fungal cells and small 
unilamellar lipid vesicles. Efficacy of K20 to suppress pulmonary cryptococcal infection 
was studied in a murine model.  
K20 exhibited broad-spectrum in vitro antifungal activities but did not inhibit 
common bacteria such as Escherichia coli, Staphylococcus aureus, and Micrococcus 
luteus. Hemolysis of sheep erythrocytes and half-maximal cytotoxicities of mammalian 
cells occurred at K20 concentrations that ranged from 10- to 32-fold higher than 
fungicidal MICs. With fluorescein isothiocyanate, 20 to 25 mg/L K20 caused staining of 
>95% of Cryptococcus neoformans and Fusarium graminearum cultures. Within 2 min, 
K20 caused leakage of 50% of calcein from preloaded small unilamellar lipid vesicles. In 
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a murine model for pulmonary cryptococcosis, K20 treatment reduced lung infection 
rates by 4-fold compared to untreated mice.  
K20 is a broad-spectrum fungicide that exhibits minimal animal cell cytotoxicity 
and suppresses pulmonary infection by C. neoformans. The fungicidal mechanism of 
action of K20 is due to pore formation in the fungal plasma membrane. K20 is a novel 
and attractive lead compound for development of a new class of therapeutic antifungals. 
INTRODUCTION 
The frequency of invasive fungal infections has increased due to the rising 
number of immunocompromised individuals resulting largely from AIDS, cancer 
chemotherapies, and bone marrow and organ transplantations.1, 2 For example, C. 
neoformans is a major fungal pathogen that causes life threating fungal infections such as 
meningitis and pneumonia in immunocompromised patients. Globally, more than 
600,000 people are killed by cryptococcal meningitis, mostly in areas with high HIV 
rates, such as sub-Saharan Africa.3 Pulmonary cryptococcosis is seen in 25 to 55% of 
patients with AIDs and cryptococcal meningitis.4 The route of cryptococcal infection 
occurs via inhalation of basidiospores into the lungs that later spread to the central 
nervous system. Currently, a limited number of antifungal drugs such as amphotericin B, 
fluorocytosine and azoles are used to treat invasive cryptococcosis in humans.5 Growing 
fungal resistance and host side effects limit their therapeutic efficacy. There is therefore a 
growing need to develop novel antifungal drugs to combat cryptococossis as well as other 
fungal diseases.  
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Aminoglycosides are compounds having two or more amino sugars bound to an 
aminoacyclitol ring via glycosidic bonds. Many are used therapeutically against bacterial 
infections of humans and animals. Among them, kanamycin A, produced by the soil 
microbe Streptomyces kanamyceticus, is one of the most successful.6,7,8 Kanamycin A is 
structurally based on sugar rings I and II of neamine with an attached ring III of O-6-
linked kanosamine. The aminoglycosides are generally viewed to act against bacteria.8 
Most bind directly to the prokaryotic 16S rRNA in the decoding region A site, leading to 
the formation of defective cell proteins. Despite being mainly antibacterial, certain 
classical aminoglycosides are also found to inhibit crop pathogenic fungal oomycetes,9 
and certain structurally unusual ones inhibit yeasts and protozoans.10 Previously, we 
reported a novel aminoglycoside FG08 with broad-spectrum antifungal properties that did 
not inhibit tested bacterial and mammalian cells. FG08 differs from kanamycin B by 
substitution of a C8 alkyl chain at the 4″- O position of ring III.11 Despite these 
properties, FG08’s development as a lead antifungal agent is limited. Incorporation of the 
C8 alkyl chain at the kanamycin B 4″-O position is difficult and the product yield is low. 
These shortcomings prompted the search for structurally similar aminoglycosides using 
alternative synthetic approaches. Here, we describe aminoglycoside K20 (Figure 3-1) that 
is structurally similar to FG08 and also possesses broad-spectrum antifungal activities. 
K20 is derived from kanamycin A by substitution of an octanesulfonyl chain at 6″- O 
position of ring III and is amenable to scalable production.12 
In this study, we report activities of K20 against fungal species that include 
several animal and plant pathogens, and we evaluate its cytotoxicity to erythrocytes and 
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mammalian cells. We investigated K20’s antifungal mechanism using intact fungal cells 
and with model lipid bilayer membranes (also called SUVs). Finally, the efficacy of K20 
to prevent the establishment of pulmonary cryptococcosis infection was determined in a 
mouse model. In summary, K20 exhibits antifungal activity against a broad range of 
fungal species, increases membrane permeability as its mechanism of action, is relatively 
non-toxic to mammalian cells, and shows therapeutic efficacy against pulmonary 
cryptococcosis infection. 
MATERIALS AND METHODS 
K20 
Aminoglycoside K20 was synthesized from kanamycin A as previously 
described.12 A 10 g/L stock solution was prepared in twice distilled water and stored at 
5oC. 
Organisms and culture conditions 
F. graminearum strain B-4-5A was obtained from the Small Grain Pathology 
Program, University of Minnesota, Minneapolis MN, USA.  E. coli TGI, S. aureus 
ATCC6538, M. luteus, R. pilimanae ATCC9449, C. albicans ATCC10231, C. albicans 
ATCC64124 and C. albicans ATCC MYA-2876 were obtained from the American Type 
Culture Collection (Manassas, VA, USA). Saccharomyces cerevisiae W303C was 
previously described.13 C. neoformans H99 was obtained from Dr. J. Perfect (Duke 
University Medical Center, Durham, NC, USA), C. neoformans 94-2586, C. neoformans 
90-26, C. tropicalis 95-41, C. pseudotropicalis YOGI, and C. lusitaniae were obtained 
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from Dr. J. Takemoto (Utah State University, Logan, UT, USA). Aspergillus flavus, A. 
niger, Rhizopus stolonifer, F. oxysporum, Ulocladium spp., F. culmorum, Microdochium 
nivale, Verticillium spp., Mucor haemalis and Cladosporium cladosporioides were 
obtained from Dr. B. Kropp (Utah State University, Logan, Utah, USA). Filamentous 
fungi and yeasts were cultivated in potato dextrose broth (PDB) (Difco, BD, Franklin 
Lakes, NJ, USA) at 28-30°C. S. cerevisiae W303C was grown in YPD (1% yeast extract, 
2% peptone, and 2% glucose) medium. Bacterial strains were grown at 37°C for 24 h on 
Luria-Bertani medium14 except S. aureus ATCC6538, which was grown on Mueller-
Hinton medium (Difco, BD, Franklin Lakes, NJ, USA). 
Yeast growth inhibition assays 
The in vitro effects of K20 on the growth of yeast strains C. neoformans H99, C. 
neoformans 94-2586, C. neoformans 90-26, R. pilimanae 9449, C. albicans10231, C. 
albicans 62124, C. albicans MYA-2876, C. tropicalis 95-41, C. pseudotropicalis YOGI 
and C. lusitaniae 95-767 were assayed in microtiter plates as described in the reference 
methods on antifungal susceptibility testing of the Clinical and Laboratory Standards 
Institute (CLSI) (formerly the National Committee for Clinical Laboratory Standards).15 
Cells were grown in PDB for 48 h, counted using a hemocytometer and diluted to a 
concentration of 5 × 104 CFU/mL in fresh PDB. Cell suspensions (100 μL) containing 
0.48 - 250 mg/L of K20 were added to the wells of a 96-well microtiter plate (uncoated 
polystyrene, Corning Costar, Corning, NY, USA) and incubated for 48 h at 30°C. Each 
test was performed in triplicate. 
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Fungal growth inhibition assays 
In vitro antifungal activity against F. graminearum, F.oxysporum, F. culmorum, 
C. cladosporioides, R. stolonifer, Ulocladium spp., M. nivale, Pencillium spp., A. flavus 
and M. haemalis was assessed as described in Lay et al. 2003.16 Spores were isolated 
from sporulating cultures growing in PDB medium by filtration through sterile glass 
wool. Microbroth dilution assays for determination of minimal inhibitory concentrations 
(MICs) were conducted using the protocols of the CSLI.17 Serial dilutions of K20 were 
made in sterile 96-well plates in the range of 250 - 0.48 mg/L and spore suspensions were 
added to make a final concentration of 5 x 105 CFU/mL. The plates were incubated at 
25°C for 48 h. Each test was performed in triplicate. 
Bacterial growth inhibition assays 
The in vitro effects of K20 on the growth of bacterial species E. coli, M. luteus 
and S. aureus were assayed in microtiter plates and MICs were determined using CLSI 
protocols.18 Cells were grown overnight in Luria-Bertani medium and diluted to a 
concentration of 1 × 104 CFU/mL. Ten μL of the diluted overnight culture were then 
added to 190 μL of Luria–Bertani medium containing K20 at concentrations ranging 
between 0.48 and 250 mg/L. The plates were incubated at 37°C without shaking for 16 h 
before determination of MICs. Experiments were performed in triplicate. 
Time kill curve studies 
Time kill curve studies were performed as described previously.19 Colonies from 
24 to 48 h cultures were suspended in 9 mL sterile water and adjusted to 1 × 108 
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CFU/mL. One mL of the adjusted fungal suspension was then added to either growth 
medium alone (control) or a solution of PDB plus an appropriate amount of K20 stock 
solution. These procedures resulted in a starting inoculum of approximately 1 × 105 
CFU/mL and a K20 concentration of 2,4 or 8 mg/L. Test solutions were incubated in a 
water bath shaker (Model G76, New Brunswick Scientific, New Jersey, USA) with 
agitation at 30°C. At 0, 4, 9, 24 and 48 h, 100 μL aliquots were removed from each 
solution and serially diluted 10-fold in sterile water. One hundred μL volumes of each 
dilution were spread on agar surfaces of potato dextrose agar [PDB containing agar (2%, 
w/v)] plates to allow growth. Colony counts were determined after incubation for 48 h. 
The experiment was performed in triplicate. The lower limit for accurate and 
reproducible quantification was 50 CFU/mL.19 
Hemolytic activity 
Hemolytic activity was determined using methods described by Dartois et al. 
200520 with modification. Sheep erythrocytes were obtained by centrifuging sheep whole 
blood at 1,000 × g, washing four times with phosphate-buffered saline (PBS), and 
resuspending in PBS to a final concentration of 108 erythrocytes mL-1. The erythrocyte 
suspension (80 μL) was added to wells of a 96-well polystyrene microtiter plate 
containing 20 μL of serially diluted K20 in water. The plate was incubated at 37°C for 60 
min. Wells with added deionized water and Triton X-100 (1% v/v) served as negative 
(blank) and positive controls, respectively. Percent hemolysis was calculated using the 
following equation: % hemolysis = [(absorbance of sample) – (absorbance of blank)] 
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×100/ (absorbance of positive control). Fifty percent hemolysis (HC50) values were 
calculated as K20 concentrations required to lyse 50% of the erythrocytes. 
Animal cell cytotoxicity assay 
C6181.9 (melanoma) cells were grown in DMEM/Ham’s F12 (1:1) containing 
10% fetal bovine serum (FBS). NIH3T3 cells were grown in DMEM (high glucose) 
medium containing 10% FBS in Corning Cell Bind flasks. The confluent cells were then 
trypsinized with 0.25%, w/v trypsin and resuspended in fresh medium (DMEM). The 
cells were transferred into 96-well microtiter plates at a density of 2 x 105 cells/mL. They 
were mixed with K20 at final concentrations of 10, 20, 50, 100 and 250 mg/L or an 
equivalent volume of sterile double distilled water (positive control). The cells were 
incubated for 24 h at 37oC with 5% CO2 in a humidified incubator. To evaluate cell 
survival, each well was treated with 10 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) for 4 h. In living cells, 
mitochondrial reductases convert the MTT tetrazolium to formazan, which precipitates. 
Formazan was dissolved using acidified sodium dodecyl sulfate (NaDodSO4) (0.01 M 
HCl) and quantified at A570 using a Synergy 4 Gen 5 spectrophotometer (BioTek 
Instruments Inc, Winooski, VT, USA). Triton X-100® (1%, v/v) gave complete loss of 
cell viability and was used as the positive control. Percent cell survival was calculated as: 
(control value – test value) × 100/control value, where control value represents cells + 
MTT – drug, and test value represents cells + MTT + drug. 
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Membrane permeabilization assay 
C. neoformans H99 (5 x 105 CFU/mL) or F. graminearum (5 x 105 conidia/mL) 
were grown for 18 h in PDB with continuous agitation.  Aliquots (500 µL) were taken 
and centrifuged for 2 min at 10,000 × g. The fungal pellet was suspended in 10 mM 
HEPES, pH 7.4, centrifuged again, and suspended in 500 µL distilled water.11 Treatment 
with K20 was 1 h at 28oC with continuous agitation at 1/2, 1 and 2 times the MIC value 
for the tested organism; 4, 8 and 25 mg/L K20 for C. neoformans cells and 7.8, 15.6 and 
32 mg/L K20 for F. graminearum hyphae. The K20 treated fungi were assessed 10 min 
after addition of fluorescein isothiocyanate (FITC) (10 g/L stock in acetone) (Sigma-
Aldrich, St. Louis, MO, USA)) to 6 mg/L as previously described21 with slight 
modification. Negative (water) and positive (Triton X-100® 1%, v/v) treatment controls 
were also prepared. Glass slides were prepared with 10 μL of each mixture and observed 
in dark-field and fluorescence (using an Olympus MWIB filter, excitation and emission 
wavelength 488-512 nm) modes with an Olympus IX81 fluorescence microscope 
(Olympus,Center Valley, PA, USA). Data was obtained from at least three independent 
experiments. 
Small unilamellar vesicles (SUVs)  
Lipids used were phosphatidylcholine from Glycine max (PC), L-α-
phosphatidylethanolamine from E. coli (PE), L-α- phosphatidylinositol sodium salt from 
G. max (PI), and ergosterol. The lipids were purchased from Sigma-Aldrich. SUVs were 
prepared by dissolving mixtures of lipids in chloroform/methanol (2:1, v/v). The mixtures 
chosen, PC, PE, PI, and ergosterol (5:4:1:2 ratios by weight) and PC and ergosterol (10:1 
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ratio by weight), mimic the lipid compositions of fungal plasma membranes.21, 22 The 
organic solvent was evaporated under a stream of nitrogen and the lipid mixture was 
allowed to dry under vacuum overnight. The dried lipid films were rehydrated in HEPES 
buffer (10 mM HEPES, 150 mM NaCl, pH 7.4) to generate SUVs with lipid 
concentrations at 10 g/L. 
Calcein release from SUVs  
Lipid films were prepared as described above and were suspended in 10 mM 
HEPES, 150 mM NaCl, pH 7.4, containing 60 mM calcein (self-quenching 
concentration).21 Liposome suspensions were sonicated for 2 min using a sonicator 
(SonicatorTM Heat System, W-220F, Ultrasonics, New York). The free calcein was 
removed by gel filtration through a Sephadex G-50 column. K20 at 31.3, 62.2, and 125 
mg/L was added to the calcein-loaded SUV suspensions (lipid concentration of 6-10 µM) 
and calcein leakage was followed by measuring fluorescence using a Synergy HT 
microplate reader at an excitation wavelength of 488 nm and emission wavelength of 520 
nm. Complete (100%) dye release was obtained by addition of Triton X-100® (1%, v/v). 
The dye-leakage percentage was calculated as follows: % dye 
leakage=100×(F−F0)/(Ft−F0), where F represents the fluorescence intensity 2 min after 
K20 addition, and F0 and Ft represent the fluorescence intensity without K20 and with 
Triton X-100®(1%, v/v), respectively.23 
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In vivo efficacy of K20 in treatment of mice pulmonary cryptococcosis 
RAG -/- mice lacking both T and B cells due to a defect in the recombination 
antigen gene were obtained from Jackson Laboratories (Bar Harbour, ME, USA) and 
maintained at the Montana State University Animal Resource Center (Bozeman, MT, 
USA). Cryptococcosis infection was induced in RAG-/- mice by methods as described 
previously.24 Three groups of mice were compared and each group consisted of 5 mice 
per therapy. Group A received one dose of 100 µL of 200 mg/L K20 in phosphate 
buffered saline (PBS,10 mM phosphate, 2.7 mM KCl and 137 mM NaCl, pH 7) by 
intratracheal instillation alone, group B received 100 µL of 200 mg/L K20 mixed with 
3x105 Cryptococcus yeast cells/mL, and group C received Cryptococcus cells mixed in 
PBS only. Mice were monitored for signs of distress and their weight recorded daily over 
the course of infection. Weight loss or gain was plotted as percent of weight change. 
Mice were euthanized if weight loss exceeded 25%. At day 15 post-infection, lungs were 
removed, and homogenized in 5 mL PBS. Lung cryptococcal burden was assessed by 
plating 100 µL of the homogenized suspension onto YPD agar plates at 1:10, 1:100, and 
1:1000 dilutions in PBS, incubated for 3 days, and colonies counted.  
RESULTS 
In vitro antifungal activities 
The MICs of K20 against an array of agriculturally and clinically important fungi 
and bacteria are given in Table 3-1. K20 MICs against Gram-positive and Gram-negative 
bacteria were 65- to 125-fold higher than shown by kanamycin A (Table 3-1). In contrast, 
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K20 inhibited a variety of fungi, with MICs ranging between 8-128 mg/L for yeasts and 
7.8-62.5 mg/L for filamentous fungi (Figure 3-2). Among the yeasts tested, C. 
neoformans strains were consistently the most susceptible to inhibition by K20.  
Time kill curves 
The time kill curves for K20 and C. neoformans H99, showed that an MIC level 
of K20 (4 mg/L) reduced the CFU/mL by ≥2 log10 units (Figure 3-3). However, a 2 × 
MIC level (8 mg/L) of K20 was required to achieve a fungicidal effect (100% killing). At 
4 mg/L (1 × MIC), K20 exhibited a fungistatic effect after 10 h incubation.  
Sheep erythrocyte hemolysis 
K20 lysed less than 40% of sheep erythrocytes at 500 mg/L (Figure 3-4) which is 
>50-fold higher concentration than the antifungal MIC against C. neoformans H99. The 
HC50 value of K20 was determined to be 1g/L. Kanamycin A did not show hemolytic 
activity against sheep erythrocytes (data not shown). 
Animal cell cytotoxicity  
K20 did not show toxicity against C8161.9 and NIH3T3 cells at concentrations of 
up to 250 mg/L (Figure 3-5). The 50% inhibitory concentrations (IC50s) of K20 for both 
C8161.9 and NIH3T3 cells were greater than 250 mg/L (Figure 3-5), and at least 31-fold 
higher than the antifungal MIC against C. neoformans H99 (Table 3-1).  
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Fluorescent dye uptake  
FITC dye was used to assess the membrane-perturbation effects of K20 on the plasma 
membrane of C. neoformansH99 and F. graminearum. FITC traverses cell surface 
membranes damaged or permeabilized by external agents and concentrates intracellularly 
to impart green fluorescence.25, 26 At antifungal MICs of 8 mg/L for C. neoformans H99 
(Figure 3-6) and 15.6 mg/L for F. graminearum (Figure 3-7), K20 caused 64% and 90% 
FITC cell staining, respectively. In contrast, < 5% of yeast cells and nearly no hyphae 
were stained when exposed to kanamycin A (50 mg/L). Unexposed cells were negligibly 
stained (< 2%) (Figures 3-8 and 3-9). K20 caused dose-dependent FITC staining of 
hyphae and yeast cells with complete (100%) staining achieved with 25 and 32 mg/L, 
respectively (Figures 3-6 and 3-7). 
SUV calcein release assays 
To further study the fungal membrane action of K20, SUV model membranes 
representing fungal cell membranes were prepared and evaluated. K20 showed dose- 
dependent effects on release of calcein from the SUVs. Within 2 min, K20 (30 mg/L) 
caused 50% calcein leakage from SUVs composed of PC, PE, PI, and ergosterol (5:4:1:2 
by weight) and of PC and ergosterol (7:3 by weight) (Figure 3-10). At 62.5 mg/L, K20 
caused >80% leakage from both types of SUVs within 2 min (Figure.3-8). SUVs without 
added K20 or treated with Triton X-100® showed < 10% or 100% calcein leakage, 
respectively. 
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In vivo efficacy of K20 against mice pulmonary cryptococcosis infection 
Both C. neoformans H99-infected and non-infected mice treated intratracheally 
with K20 maintained their body weights over a 15 day infection time course. In contrast, 
non-treated but infected mice showed weight losses starting at day 10 post-infection 
(Figure 3-9). In K20-treated infected mice, lung fungal burdens were decreased 4-fold (p 
= <0.01) in comparison to untreated infected mice (Figure 3-9A). Stained images of lung 
homogenates also showed decreased fungal burdens in infected mice treated with K20 as 
compared to non-treated mice (Figure 3-10B-C).  
DISCUSSION 
Recently we reported a novel aminoglycoside analog of kanamycin B, FG08, 
possessing broad spectrum antifungal activities.11, 26 FG08 differs from kanamycin B by 
the attachment of a C8 alkyl chain at the 4″-O position of ring III and greatly diminished 
antibacterial properties.11 Structure/bioactivity studies identified FG08 from among a set 
of kanamycin B analogs with varied lengths and positions of the alkyl chain as exhibiting 
the greatest antifungal properties.11 However, the synthesis of FG08 is technically 
difficult. It requires numerous chemical synthesis steps and has a low overall yield. In 
contrast, production of K20, derived from kanamycin A by the substitution of an 
octanesulfonyl chain at the 6″- O position of ring II, requires only three chemical 
synthesis steps and has a high overall yield. Like FG08, the structurally related K20 
displays broad-spectrum antifungal activities but not antibacterial activities (Table 3-1). It 
thus appears that the fungicidal activity of K20 is due to the incorporation of an 
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octanesulfonlyl chain to the 6″-O position of III ring of kanamycin A. Interestingly, K20 
is slightly more active against filamentous fungi (except for A. flavus) than against yeasts. 
Exceptions are C. neoformans strains with susceptibilities to K20 at relatively low MICs 
(Table 3-1). K20 exhibited dose-dependent fungicidal activity against C. neoformans H99 
that completely suppressed the growth of H99 strain at 8 mg/L after 10 h (Figure 3-3).  
In order to distinguish between selective antimicrobial activity and non-selective 
lytic activity, we measured the toxicity of K20 against sheep erythrocytes and living 
mammalian cells. At and above antifungal MICs, K20 did not lyse sheep erythrocytes 
(Figure 3-3) and did not inhibit the proliferation of NIH3T3 and C6181.9 cells (Figure 3-
4). These results confirm the selective killing of K20 against fungi.  
Due to the octanesulfonyl chain at the 6″- O position, K20 assumes an 
amphipathic character that suggests interaction with cell membranes. To study the 
possibility for a membrane-targeted antifungal mechanism of action by K20, its effects 
on the cellular uptake of excess FITC dye were measured with C. neoformans H99 and F. 
graminearum. FITC uptake only occurs when the plasma membrane is damaged or 
permeabilized. Once FITC enters a cell, it binds to cellular proteins and can be visualized 
as a green fluorescence.25, 26 At antifungal MICs, K20 caused rapid FITC dye uptake by 
C. neoformans H99 cells and F. graminearum hyphae within 10 min of incubation. K20 
was >12-fold more effective than kanamycin A. Similar effects on FITC dye uptake by S. 
cerevisiaeW303C with exposure to FG08 were previously observed.26 To further study 
membrane perturbation effects of K20, calcein leakage studies were conducted with 
model lipid bilayer membranes, SUVs. SUVs were produced with glycerophospholipid 
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and sterol compositions that mimic those of fungal plasma membranes.22, 23 At MICs 
shown for yeasts, K20 caused the rapid release of calcein from SUVs. The rapidity of dye 
influx by cells (10 min) and calcein leakage (2 min) from SUVs suggests that K20’s 
growth inhibitory effect is due to direct and rapid effects on plasma membrane 
permeability. The results also show that K20, in contrast to its parent molecule 
kanamycin A, is altered not only in the group of organisms it targets, but it also has an 
altered mode of action. Kanamycin A targets protein translation, whereas K20 acts 
through membrane perturbation. 
An in vivo efficacy study of K20 was conducted in a mouse model to determine 
its capabilities for preventing the establishment of pulmonary cryptococcosis. K20 
significantly prevented the establishment of pulmonary cryptococcus infection in mice 
when C. neoformans H99 was administered intratracheally, showing that even a single 
initial treatment of K20 made a significant difference (p = <0.01) in the propagation of 
the fungal pathogen. Animal toxicity effects of K20 were not evident as both infected and 
non-infected mice treated with K20 (at 10-fold MIC) maintained their weight for 15 days 
post-infection. Untreated, infected mice showed weight losses starting at day 10 post-
infection.  
In conclusion, a novel aminoglycoside analog of kanamycin A, K20, with an 
octanesulfonyl chain as a major structural feature, is a broad spectrum fungicide and is 
not antibacterial. K20 is not hemolytic and showed low mammalian cell toxicities. The in 
vivo efficacy of K20 to prevent the establishment of pulmonary cryptococcosis in mice 
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suggests the therapeutic application of K20 in medicine in addition to its potential as a 
crop protectant in agriculture. 
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Table 3-1.Minimal inhibitory concentrations (MICs) of K20and kanamycin A against 
bacteria and fungi 
 
Organism        aMIC (mg/L) 
 
        K20  kanamycin A 
 
Yeasts 
Cryptococcus neoformans H99 4-8  >125 
Cryptococcus neoformans 94-2586   4-8  >125 
Cryptococcus neoformans 90-26   15.6 nd 
Candida pseudotropicalis YOGI   31  .  nd 
Candida lusitaniae 95-767    31.5  .  nd 
Candida rugosa 95-967    62.5 .nd 
Candida tropicalis 95-41    31  .  nd 
Candida albicans 10231    31.3-128 >250 
Candida albicans 62124    300  >500 
Rhodotorula pilimanae 9449    15.6  >250 
Saccharomyces cerevisiae W303C   15.6-31.3 >250 
Filamentous fungi 
Fusarium graminearum B-4-5A   15.6  >125 
Fusarium oxysporum     31.3  >250 
Fusarium culmorum     7.8  ..bnd 
Microdochium nivale      3.9      nd 
Mucor haemalis     15.6  >125 
Ulocladium spp.     15.6  >125 
Penicillium spp     31.3       nd 
Rhizopus stolonifer     15.6  >250 
Cladosporium cladosporioides   31.3      nd 
Aspergillus flavus     >500      nd 
Aspergillus niger     500      nd 
Bacteria 
Escherichia coli TG1     125-250   1.95 
Staphylococcus aureus ATCC 25923    250  <0.98 
Micrococcus luteus     62.5    1.95 
___________________________________________________________________ 
aMicrobroth dilution assays were performed at least twice, and each in triplicate. 
b not determined 
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                 Figure 3-1. Structures of aminoglycosides FG08, kanamycin A, and K20. 
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Figure 3-2. Microscopic images of F. graminearum and C. neoformans H99 suspended 
and incubated in PDB in microtiter plate wells of MIC microbroth dilution assays. Shown 
are F. graminearum macroconidia at 0 h (a1), after 24 h (a2), after 24 h with 15.6 mg/L 
K20 (a3), and after 48 h with 62.5 mg/L kanamycin A (a4) and C. neoformans H99 cells 
(5 X 10-4 CFU/mL) at 0 h (b1), after 24 h (b2), after 24 h with 8 mg/L K20 (b3), and after 
48 h with 62.5 mg/mL kanamycin A (62.5 mg/L) (b4). 
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Figure 3-3. Time kill curves for C. neoformans H99 at different concentrations of K20: 
control (no drug) (filled triangles), 2 mg/L (open triangles), 4 mg/L (filled circles), and 8 
mg/L (open circles). 
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Figure 3-4.Hemolytic activity of K20 (white bars) against sheep erythrocytes after 1 h 
exposure at37°C. Positive control (100% hemolysis) was provided by treatment with 
Triton X100® (1%, v/v) (black bar). Negative control (grey bar) without drug. 
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Figure 3-5.Mammalian cell cytotoxicities of K20.MTT cytotoxicities of NIH3T3 mouse 
fibroblast cells (white bars) and C8161.9 melanoma cells (grey bars) with 24 h exposure 
to K20 at various concentrations. Positive control (0% cell survival) was provided by 
treatment with Triton X100®(1%, v/v) (black bar). 
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Figure 3-6. Dose-dependent membrane perturbation effects of K20 on C. neoformans 
H99. FITC dye uptake without (a1, a2) and with K20 (4 mg/L) (b1, b2), (8 mg/L) (c1, c2) 
and (25 mg/L) (d1, d2) exposure for 10 min. Bright-field images (a1, b1, c1 and d1) are 
compared with fluorescence images (a2, b2,c2 and d2). Bar length is 10µm. Panel (e1) 
shows dose-dependent effects of K20 on FITC dye uptake and effects of kanamycin A 
and no treatment Triton X-100® (1%,v/v) gave 100% dye influx (data not shown). The 
error bars show SD from analyses of 10 separate microscopic image fields randomly 
selected from at least two separate experiments.  Numbers above the range bars indicate 
the number of cells analyzed. 
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Figure 3-7.Dose-dependent membrane perturbation effects of K20 on F. graminearum. 
FITC dye uptake without (a1, a2) and with K20 (7.8 mg/L) (b1, b2), (15.6 mg/L) (c1, c2) 
and (32 mg/L) (d1, d2) exposure for 10 min. Bright-field images (a1, b1, c1 and d1) and 
fluorescence images (a2, b2, c2 and d2). Image a2 (no FG08 and no kanamycin A) shows 
no fluorescent cells against a fluorescent background. Bar length is 10µm. Triton X-100® 
(1%, v/v) gave 100% dye influx (data not shown). 
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Figure 3-8.Effect of K20 on calcein release from SUVs that mimic fungal plasma 
membranes.Calcein released from SUVs made with PC/PE/PI/ergosterol (5:4:1:2) (a) and 
PC/ergosterol (7:3) (b) were exposed to 30 (open circles), 62.5 (open triangles), and 125 ( 
open squares) mg/L K20, kanamycin A (62.5 mg/L) (filled triangles) and Triton X-100® 
(1%) (filled circles). Data compiled from three separate experiments. 
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Figure 3-9. Mean percent weight change in groups of mice receiving treatments of K20 
(filled circles), infected with C. neoformans H99 and treated with K20 (open triangles), 
and infected with C. neoformans H99 and with no K20 treatment (filled squares). 
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Figure 3-10. (a) Mouse pulmonary fungal burden at day 15 post-C. neoformans infection 
as assessed by plating for CFU. Grey bar, K20 alone; white bar, no K20 treatment; black 
bar, K20 treated infected mice. (b) Image of lung homogenate prepared from non-treated 
mice and (c) K20-treated mice 15 days after C. neoformans infection.  
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CHAPTER 4 
ANTIFUNGAL SYNERGISM BETWEEN AMINOGLYCOSIDE K20 AND AZOLE 
ANTIFUNGALS 
 ABSTRACT  
Opportunistic invasive fungal infections are a major cause of morbidity and 
mortality in immunocompromised patients. Candida, Cryptococcus and Aspergillus are 
three major opportunistic human pathogens that cause an increasing number of systemic 
fungal infections in critically-ill patients. Azoles are widely used antifungals to treat these 
infections. But the increasing frequency of cross-resistance against azoles requires 
improved therapeutic strategies. Recently, a novel aminoglycoside, K20, derived from 
kanamycin A, was shown to be inhibitory to filamentous fungi, yeasts and oomycetes, but 
not to bacteria. In this study, combinations of K20 and six azoles were investigated to 
establish whether antifungal synergy exists against Candida and Aspergillus. 
Checkerboard microdilution methods and time-kill curves were used to assess 
synergistic, indifferent and antagonistic effects, with K20 used in combination with 
fluconazole, itraconazole, voriconazole, clotrimazole, ketoconazole, and posaconazole. 
The interactions were assessed by calculation of fractional inhibitory concentration 
indices. Time kill curve and disk diffusion assays were performed to confirm the 
synergistic interaction between these drugs.  
All six azoles showed antifungal synergy in combination with K20 against two 
azole-resistant Candida albicans strains, 10231 and 64124, and one azole sensitive strain, 
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MYA 2876, with mean fractional inhibitory concentration indices ranging from 0.09 - 
0.37. However, only itraconazole, and posaconazole were synergistic with K20 against 
Aspergillus flavus, with mean fractional inhibitory concentration indices ranging from 
0.22 - 0.37. A time kill curve performed by colony counting confirmed the synergistic 
interactions of K20 and azoles, with a ≥ 2 log10 decrease in CFU/mL compared with the 
corresponding azoles alone. 
K20 showed potent antifungal synergism when combined with each of six well-
known azoles against C. albicans strains and with two azoles against A. flavus. These 
results suggest that combination therapies of K20 and azoles may represent a new and 
effective strategy to combat invasive fungal infection caused by azole-resistant C. 
albicans and A. flavus. 
INTRODUCTION 
The frequency of invasive fungal infections has increased due to the rising 
number of immunocompromised individuals resulting largely from AIDS, cancer 
chemotherapies, and bone marrow and organ transplantations (1, 2). Candida albicans, 
Cryptococcus neoformans and Aspergillus fumigatus are the major human fungal 
pathogen associated with unacceptably high mortality rates of 20-40 % (3), 20-70 % (4), 
and 50-90 % (3), respectively, in immunocompromised patients. Several studies have 
also estimated that 6-11 % of all positive nosocomial bloodstream infections could be 
attributed to Candida spp. (5, 6).  
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Currently, azoles have emerged as the first-line drugs used to treat various fungal 
infections including candidal infections in critically ill patients (7). However, the major 
weakness of azoles as an antifungal agent is that they are fungistatic. Their efficacy 
depends on the degree of host immunity and is thus lacking in immunocompromised 
patients (7). In addition, the fungistatic properties of azoles are predicted to promote 
development of fungal resistance that further complicates the management of fungal 
disease (8). Therefore, new strategies for the treatment of invasive fungal infections are 
warranted. Previously, promising results were observed by combining azoles with 
different compounds such as tacrolimus (FK506), cyclosporine A, amiodarone, and 
retigeric acid B against C. albicans strains (9, 10, 11, and 12). The combination therapy 
of azoles with other antifungal or non-antifungal agents may lead to new antimicrobial 
therapies. 
Aminoglycosides are compounds having two or more amino sugars bound to an 
aminoacyclitol ring via glycosidic bonds. Many are used therapeutically against bacterial 
infections of humans and animals. Among them, kanamycin A, produced by the soil 
microbe Streptomyces kanamyceticus, is one of the most successful (13, 14, 15). 
Kanamycin A is structurally based on sugar rings I and II of neamine with an attached 
ring III of O-6-linked kanosamine. The aminoglycosides are generally viewed to act 
against bacteria (15). Most bind directly to the prokaryotic 16S rRNA in the decoding 
region A site, leading to the formation of defective cell proteins. Despite being mainly 
antibacterial, certain classical aminoglycosides are also found to inhibit crop pathogenic 
fungal oomycetes (16), and certain structurally unusual aminoglycosides inhibit yeasts 
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and protozoans (17). Recently, we reported a novel aminoglycoside K20 that is derived 
from kanamycin A by substitution of an octanesulfonyl chain at the 6″- O position of ring 
III (18). K20 exhibited broad-spectrum antifungal activity but did not inhibit tested 
bacterial and mammalian cells. Because of its broad-spectrum antifungal activity and 
feasibility for mass production, K20 may be a good candidate for therapeutic use in 
medicine. However, synergistic effectiveness of K20 and azoles on antifungal action has 
not been explored. In this study, we investigated the combined effects of six azoles and 
K20 against clinically important fungal isolates by the checkerboard microbroth dilution 
method, time kill curves and disk diffusion assays. 
MATERIALS AND METHODS 
Antifungal agents 
Aminoglycoside K20 was synthesized from kanamycin A as previously described 
(18). A 10 g/L stock solution was prepared in twice distilled water and stored at 5oC.The 
antifungal agents fluconazole (FLC), ketoconazole (KTZ), and chlotrimazole (CTZ) 
(Sigma- Aldritch); voriconazole (VRC) and posaconazole (POS) (Selleck Chemical, 
Houston, Texas), itraconazole (ITC) (Cayman Chemical, Ann Arbor, MI); metconazole 
(BASF corporation) were from commercial sources. FLC was dissolved in distilled water 
at a final concentration of 2.5 mg/mL. KTZ, CTZ, ITC, VRC, and POS were dissolved in 
DMSO at final concentrations of 5 mg/mL for each.  
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Organsims and culture conditions 
Azole-resistant (azole-R) strains C. albicans ATCC 64124 and C. albicans ATCC 
10231 and azole-sensitive (azole-S) C. albicans ATCC MYA-2876 were obtained from 
the American Type Culture Collection (Manassas, VA, USA). A. flavus was obtained 
from Dr. B. Kropp (Utah State University, Logan, Utah, USA). Yeasts and filamentous 
fungi were cultivated in potato dextrose broth (PDB) (Difco, BD, Franklin Lakes, NJ, 
USA) at 30 – 35oC. 
Inoculum preparation 
All C. albicans strains were grown on potato dextrose agar medium (PDA) for 48 
h at 35oC. A single colony of each isolate was then used to inoculate 5 mL of PDB and 
incubated for 24 h at 35oC. Similarly, A. flavus was grown in PDB for 7 days at 30oC. 
Spores were isolated from sporulating cultures growing in PDB medium by filtration 
through sterile glass wool. The cells were titrated using a hemocytometer to attain the 
inoculum size of 2 × 106 CFU/mL for both yeasts cells and fungal spores in PDB 
medium. Finally, the inoculum size was verified by plate colony count method on PDA. 
Antifungal susceptibility testing 
In order to choose the appropriate range of drug concentrations for the 
combination studies, the minimal inhibitory concentrations of K20 and azoles against 
yeast strains and filamentous fungi were assayed in 96 well microtiter plates as described 
in CLSI M-27-A2 (19) for yeasts and CLSI M-38-A for filamentous fungi (20). Two- 
fold serial dilutions of K20 and azoles were made in sterile 96-well plates (uncoated 
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polystyrene, Corning Costar, Corning, NY, USA) in the range of 0.48 - 250 mg/L for 
K20 and fluconazole and 0.048 - 25 mg/L for rest of the azoles. Cells or spores were 
added to each well except the sterility control well to achieve a final concentration of 1 × 
105 CFU/mL. The plates were incubated at 35oC for 48 h (yeasts) or 72 h (filamentous 
fungi). The fungal growth was measured using a visual observation method that was 
further confirmed using a Zeiss Invertoskop 40C (Carl Zeiss Inc., Germany). For visual 
reading, MIC was defined as the lowest drug concentration showing 80% (or more) 
growth inhibition compared to drug-free control. Each test was performed in triplicate. 
Checkerboard analysis 
The combination studies between K20 and azoles against different fungal strains 
were performed using a microdilution checkerboard technique according to CLSI M27-
A2 (19) guidelines for yeasts. Synergistic interactions were performed using 96-well flat-
bottomed microtiter plates. The final concentration of yeast cells or fungal spores was at 
a viable cell density of 1×105 CFU/mL as determined by viable cell colony counting on 
agar plates. Similarly, the final concentrations of the drugs ranged from 0.04 to 3 
μg/mL for ITC; 0.3 to 48 μg/mL for FLC; 0.01 to 1 μg/mL for VRC; 0.07 to 2.5 μg/mL 
for CTZ; 0.005 to 2 μg/mL for POS; 0.3 to 24 μg/mL for KTZ and 2 to 256 μg/mL for 
K20. Plates were incubated at 35oC for 48 - 72 h. The growth in each well was measured 
by visual observation that was confirmed using a Zeiss Invertoskop 40C (Carl Zeiss Inc., 
Germany) in the same manner as antifungal susceptibility testing. Each experiment was 
performed in triplicate.  
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Interaction model 
A non-parametric model, the FICI model that is based on a no interaction theory 
Loewe additvity (LA) (21) was used to evaluate the interaction nature of K20 and azoles. 
The LA theory is based on the idea that a drug cannot interact with itself. In the LA-based 
model, concentrations of the drugs, alone or in combinations, which produce the same 
effect, are compared. According to LA theory, FICI can be defined as the sum of the MIC 
of each drug when used in combination divided by the MIC of the drug used alone.  Drug 
interactions were classified as synergistic, indifferent, or antagonistic according to the 
fractional inhibitory concentration index (FICI). The interaction was defined as 
synergistic if the FICI was ≤0.5, indifferent if >0.5 - 4, and antagonistic if >4 (21). 
Time kill curves 
Time kill curves were performed to study the activity of K20 with or without ITC 
or FLC against azole resistant C. albicans 10231. The strain C. albicans 10231 was 
prepared at the starting inoculum of 105 CFU/mL in PDB medium. A set of solutions was 
prepared a drug-free growth control, K20 alone (32 μg/mL), ITC alone (0.18 or 0.37), 
FLC alone (12 μg/mL), and combinations of K20 with each azole. All solutions were 
incubated at 35oC with continuous agitation (22). At various time points (0, 3, 6, 9, 24 
and 48 h after incubation), a 100 μL aliquot was removed from each solution and serially 
diluted 10-fold in sterile water. A volume of 100 μL of each dilution was spread on the 
PDA plate to allow growth. Colony counts were determined after incubation for 48 h. 
The experiment was performed in triplicate. For antifungal interactions tested by time-kill 
methods, the following criteria are commonly followed: (i) synergy is defined as a ≥2 
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log10 decrease in CFU/mL compared to the most active constituent; (ii) antagonism is 
defined as a ≥2 log10 increase in CFU/mL compared to the least active agent (22). 
Disk diffusion assay 
C. albicans MYA-2876 (azole-S) and C. albicans 64124 (azole-R) yeast cells at a 
cell density of ∼5 × 105 were spread onto PDA medium. A sterile Whatman paper disk (7 
mm) was placed on top of the PDA. For azole-S strain, either 10 μL of water, ITC (0.5 
μg/mL), K20 (32 μg/mL), or their combination (0.5 μg/mL, ITC plus 32 μg/mL, K20) 
were applied on the filter disks. Similarly, for azole-R strain, 10 μL of water, ITC (800 
μg/mL), K20 (1000 μg/mL), or their combination (800 μg/mL, ITC plus μg/mL, K20) 
were applied on the filter disks. The cells were incubated for 24-48 h at 30°C. 
RESULTS 
Antifungal susceptibility testing 
K20 showed a weak inhibitory effect against azole-S C. albicans MYA2876, 
azole-R C. albicans 64124 and A. flavus, with MICs ranging between 128 µg/mL, and 
1250 µg/mL (Table 4-1). Among azoles, POS had the strongest activity against all tested 
fungi with MICs ranging from 0.15 - 6 µg/mL, followed by CLZ (0.5 - 6 µg/mL). ITC 
and VRC were also active with all of the fungal strains except for C. albicans 64124, 
with MICs ranging between 0.37 - 48 µg/mL (ITC) and 0.015-64 µg/mL (VRC). 
Conversely, all of the tested fungal strains significantly less sensitive to KTZ (MICs 
ranging from 6 - 25 µg/mL) and FLC (MICs ranging from 48 - 400 µg/mL) (Table 4-1). 
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Interaction between K20 and azoles 
The nature of the interaction between K20 and azoles was evaluated by the non-
parametric FICI model. The MICs of K20 and azoles, alone and in combination against 
tested fungal strains, are summarized in Table 4-1. K20 exhibited strong synergy with all 
six azoles tested against azole resistant C. albicans strains 10231 and 64124, and one 
azole sensitive strain, MYA 2876, with mean fractional inhibitory concentration indices 
ranging from 0.09 - 0.37. However, only POS and ITC in combination with K20 showed 
synergy against A. flavus, with an FICI value of 0.37 for both azoles. The mean MICs of 
azoles in the presence of K20 and K20 in presence of azoles were reduced by 4-fold to 
65-fold, and 8-fold to 32-fold, respectively, against tested fungal strains. For example, the 
MIC of FLC against azole-S strain C. albicans MYA 2876 decreased from 300 µg/mL 
when tested alone to 4.6 µg/mL in the presence of K20, a decrease of 65-fold (Table 4-1).  
Time kill curves 
The synergistic interaction of ITC and FLC in combination with K20 was 
confirmed by time kill curves against one chosen azole-R C. albicans 10231 (Figure 4-1). 
In the presence of 32 µg/mL K20, growth of C. albicans was comparable to the growth 
control. Likewise, at the concentrations used, ITC (0.37 µg/mL) and FLC (12 µg/mL) 
alone showed fungistatic effect after 24 h growth.  However, ITC-K20 (0.37 - 32 µg/mL) 
and FLC-K20 (12 - 32 µg/mL) combination therapy yielded a ≥2 log10 decrease in 
CFU/mL compared with each compound alone. The K20-azole combinations showed 
significant reduction in candidal growth at 3 h and 6 h and completely killed by 9 h of 
treatment. 
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Disk diffusion 
To further reconfirm the synergistic interaction of K20 with azoles, the 
susceptibility of azole-R C. albicans 64124 and azole-S C. albicans MYA2876 strains to 
K20, ITC and POS alone and in combination was analyzed by disk diffusion assay. As 
shown in Figure 4-2, K20 alone at 500 and 1000 µg/mL per disk did not show inhibition 
against azole-R C. albicans 64124. Interestingly, when combined with POS (100 µg/mL) 
or ITC (800 µg/mL), notable zones of inhibition were observed. Similarly, K20 alone at 
32 µg/mL per disk did not show inhibition against azole-S C. albicans MYA2526 but 
when combined with 0.5 µg/mL of ITC or 2 µg/mL of POS, zones of inhibition were 
observed (Figure 4-2).  
DISCUSSION 
Invasive fungal infections are on the rise as the number of patients with 
compromised immune systems continues to increase (1). The antifungal therapies that are 
currently available show limited clinical efficacy to some invasive fungal infections, such 
as candidiasis, aspergillosis and cryptococcosis. Currently, azoles are the first-line drugs 
that have been shown to be as effective as amphotericin B against various fungal 
infections. However, the major weakness of azoles as an antifungal agent is they are only 
fugistatic, and they also tend to promote fungal resistance. This has expanded the need 
for the discovery of novel antifungal agents or the new strategies to keep fungal 
infections at bay. The combination therapy of azoles with other antifungal or non-
antifungal agents may lead to new antimicrobial therapies  
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A novel aminoglycoside analog K20, was shown to have promising antifungal 
activities against fungi (16), being slightly more active against filamentous fungi (except 
for A. flavus) than against yeasts (except for C. neoformans strains). In this study, K20 
exhibited high MICs against C. albicans strains and A. flavus which were consistent with 
the previous results of K20 on antifungal susceptibility testing. Similarly, ITC, POS, 
CLZ, and VRC showed good sensitivity to all tested fungal strains (except for C. albicans 
64124) with the MICs ranging from 0.015 - 3 µg/mL (Table 4-1). Interestingly, all of the 
candidal strains were resistant to FLC and moderately resistant to KTZ, with MICs 
ranging from 48 - 400 µg/mL and 6 - 25 µg/mL, respectively.  
Checkerboard microdilution technique was performed to understand interaction of 
K20 and azoles against three strains of C. albicans and one strain of A. flavus in vitro. 
The nature of interactions between these two drugs was evaluated by an FICI model. To 
minimize the experimental error in determining FICI values, triplicate experiments 
performed for each strain for combination studies were considered as one outcome. The 
data showed promising synergy between K20 and all six azoles against tested fungi 
except for A. flavus, with FICI values >0.5. Interestingly, only PSC-K20, and ITC-K20 
combinations showed synergy against A. flavus (Table 4-1). Antagonism was not 
observed between K20 and azoles with any of the strains tested.  
The synergistic interactions by checkerboard microdilution were confirmed by a 
time-kill test in this study. This method is widely used because this provides growth 
kinetic information and the effect of combination therapy on cell viability over time (20). 
ITC and FLC in combination with K20 against one chosen strain, C. albicans 10231, 
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showed a ≥2 log10 decrease in CFU/mL compared with ITC, FLC or K20 alone after 3 h 
of incubation. These combination therapies also showed a fungicidal effect by 9 h. This is 
in contrast to the fungistic effect of azoles when used alone (Figure 4-2). Agreement was 
seen between the FICI method and the time-kill curves for all fungal strains tested.  
Disk diffusion assay was further used to reconfirm the synergistic interaction between 
K20 and azoles. K20, ITC and POS alone at investigated concentrations did not produce 
clear zones of inhibition against azole-R and azole-S C. albicans. Interestingly, when ITC 
and PSC were combined with K20, they produced notable zones of inhibition against 
tested strains, suggesting the synergistic interaction between K20 and azoles does exist. 
Azoles act by inhibition of 14-alpha-demethylase, the enzyme that converts 
lanosterol to ergosterol in fungi.   This leads to the accumulation of 14-methylated sterol, 
which can cause disruption of the fungal membrane (23, 24). Previously, our study on the 
mechanism of action of K20 revealed that it acts on fungi by disrupting the fungal 
membrane. However, the exact molecular target for K20 is yet to be determined. It has 
been reported that novel aminoglycoside FG08 exhibits a membrane lipid-modulated 
mechanism of action against fungi (25). K20 is believed to have the similar mode of 
action against fungi. Although, the mechanism of synergistic interaction with azoles 
remains unclear at present, it could be presumed that both K20 and azoles target different 
molecular sites in the fungal plasma membrane. This may facilitate the swift 
destabilization of the fungal plasma membrane, thus augmenting the fungicidal activity. 
We have also previously reported the low cytotoxicity profile of K20 against animal cells 
in vitro and in vivo, thus, K20 is potentially a good candidate for use as a therapeutic 
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antifungal agent. The use of K20 in combination with azoles may provide further 
improvement in treating invasive fungal infections in medicine.  
In conclusion, our study demonstrates the synergistic combination effects between 
K20 and six azoles against tested C. albicans strains. These synergistic interactions were 
further confirmed by time kill curves and disk diffusion assay. K20-azoles combination 
therapy might be mainly beneficial to treat invasive fungal infections like candidiasis and 
aspergillosis. However, rigorous animal model studies are required to validate the 
significance of K20-azole combination as a potential antifungal therapy and further 
studies with wide array of clinical isolates are needed.  
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Table 4-1. Suceptiblility of fungal strains to K20 and azoles alone and in combination 
 Mean MIC (µg/mL)  
drug alone drug in 
combination 
Combination Strains azole K20 azole K20 FICI Interpretation 
FLC+K20 C. albicans 64124    400 300 100 75 0.37 Synergy 
C. albicans 10231      >48 128 3 16 0.18 Synergy 
C. albicans MYA2876 300 128 4.6 8 0.09 Synergy 
A. flavus nd nd nd nd nd nda 
 
POS+K20 C. albicans 64124    6 300 0.37 37.5 0.18 Synergy 
C. albicans 10231      0.75 128 0.09 16 0.24 Synergy 
C. albicans MYA2876 nd 128 nd nd nd nd 
A. flavus 0.15 1000 0.019 125 0.37 Synergy 
 
ITC+K20 C. albicans 64124    48 300 6 75 0.37 Synergy 
C. albicans 10231      >3 128 0.18 32 0.31 Synergy 
C. albicans MYA2876 1 128 0.03 32 0.28 Synergy 
A. flavus 0.37 1250 0.04 156.2 0.22 Synergy 
 
VRC+K20 C. albicans 64124    64 300 4 37.5 0.18 Synergy 
C. albicans 10231      1 128 0.125 4 0.15 Synergy 
C. albicans MYA2876 0.015 128 0.003 8 0.31 Synergy 
A. flavus 0.5 625 0.125 312.5 0.75 Indifference 
 
CLZ+K20 C. albicans 64124    6 300 0.75 37.5 0.25 Synergy 
C. albicans 10231      1.25 128 0.15 8 0.18 Synergy 
C. albicans MYA2876 2 128 0.06 32 0.28 Synergy 
A. flavus >2 1250 nd nd nd nd 
 
KTZ+K20 C. albicans 64124    25 150 6.25 18.7 0.37 Synergy 
C. albicans 10231      24 128 1.5 32 0.31 Synergy 
C. albicans MYA2876 12 128 1 32 0.33 Synergy 
A. flavus 6 1250 0.75 625 0.62 Indifference 
and, not determined 
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Figure 4-1. Time kill curves of ITC or FLC and K20 alone and in combination against 
azole-R C. albicans 10231. (A) C. albicans cells were exposed to K20 at 32 µg/mL(◊), 
ITC at 0.37 µg/mL(▲) or 0.18 µg/mL(×), K20 + ITC at 32 + 0.18 µg/mL(Δ) or at 32 + 
0.37 µg/mL(●), and no drug (■). (B) Cells were exposed to K20 at 32 µg/mL (◊), FLC at 
12 µg/mL(▲),  K20 + FLC at 32 + 12 µg/mL (●), and no drug (■). 
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Figure 4-2. Disk diffusion assay showing synergistic interaction of K20 with POS or ITC 
against azole-R C. albicans 64124 and azole-S C. albicans MYA 2876. Disks containing 
water, K20, ITC or the drug combinations were dried and overlaid on a lawn of yeast 
cells derived from the strains indicated. Cells were incubated for 24 h to 48 h (A) POS (2 
µg/mL) and K20 (32 µg/mL) against C. albicans strain MYA 2876; (B) POS(100 µg/mL) 
and K20 (500 µg/mL) against C. albicans strain 64124; (C) ITC (0.5 µg/mL) and K20 
(32 µg/mL) against C. albicans strain MYA 2876 (D) ITC (800 µg/mL) and K20 (1000 
µg/mL) against C. albicans strain 64124  
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CHAPTER 5 
SUMMARY AND FUTURE DIRECTIONS 
The main goals of this research were to investigate the bioactive properties and 
mechanism of action of FG08 and K20 and their synergistic interactions with azoles.  
Previously, it was shown that novel aminoglycoside FG08 exhibits promising 
antifungal activities but does not inhibit bacteria (1). However, little was known about the 
broad-spectrum bioactivities of FG08. In this study, I explored the broad-spectrum 
bioactivities of FG08 and K20 against bacteria, oomycetes, yeasts, filamentous fungi and 
mammalian cells. The results show that FG08 and K20 are broad-spectrum antifungal 
agents that do not show activity against bacteria (1, 2). In particular, FG08 was shown to 
suppress Fusarium head blight of wheat, a crop disease caused by F. graminearum and 
that results in severe economic losses worldwide (1). K20 also showed lower MICs of 
3.9-7.8 µg/mL against F. graminearumin vitro and would expect to show similar effects 
against Fusarium head blight of wheat in the greenhouse as does FG08. The results 
indicate that FG08 and K20 may be considered promising lead compounds for novel 
fungicides in agriculture.  Aminoglycosides are mainly antibacterial but some are 
reported to have mild antifungal properties (3). However, the application of 
aminoglycosides to combat bacterial or fungal diseases in agriculture is not 
recommended due to the reason that they may promote bacterial resistance. Here we 
show potentially new applications of novel aminoglycosides, FG08 and K20, as 
antifungal agents that inhibit fungi but not bacteria. Their application as fungicides in 
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agriculture, thus, seems attractive as they selectively kill fungi and will not promote the 
development of bacterial resistance.  
Fungi share many biochemical targets with eukaryotic cells and antifungal agents 
may interact with targets may also be present in eukaryotic cells, making them unsuitable 
for therapeutic use. In order to distinguish between selective antimicrobial activity and 
non-selective lytic activity, I measured the toxicity of FG08 and K20 against sheep 
erythrocytes and living mammalian cells. At and above antifungal MICs, FG08 and K20 
did not lyse sheep erythrocytes and did not inhibit the proliferation of NIH3T3 and 
C6181.9 cells. These results reveal that FG08 and K20 are not only broad-spectrum 
fungicides, but also appear to have an excellent safety profiles in terms of toxicity against 
mammalian cells. These data further expands the significance of FG08 and K20 for the 
application as antifungal agents for therapeutic use. However, the synthesis of FG08 is 
technically difficult. It requires numerous chemical synthesis steps and has a low overall 
yield. Because of this, it would not be cost effective to develop FG08 as an antifungal 
agent for commercial proposes. In contrast, production of K20 requires only three 
chemical synthesis steps and has a high overall yield. K20 exhibits broad-spectrum 
antifungal activities that are comparable to or sometimes show better activity than FG08. 
Thus, K20 appears more promising than FG08 as a lead compound for the development 
of novel antifungal agrochemicals or therapeutics. Because of this point, K20 became the 
major focus of my research. The in vivo efficacy of K20 was further explored in a murine 
model to determine its capabilities for preventing the establishment of pulmonary 
cryptococcosis. The results showed that K20 significantly prevented the establishment of 
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pulmonary cryptococcosis infection in the mouse model and did not exhibit side effects 
in the host at a high concentration of K20 (250 µg/mL). The combined observations from 
in vitro and in vivo results suggest that K20 shows promise as antifungal therapy for the 
clinical trials to treat invasive fungal infections such as pulmonary cryptococcosis. 
The antifungal mechanisms of action of FG08 and K20 were investigated using 
intact fungal cells and model lipid bilayer membranes (SUVs). The combined 
observations of FITC / SYTOX Green dye permeation, K+ efflux, and calcein leakage 
from model membranes (SUVs) showed that the selective fungicidal action of FG08 
against fungi is due to increasing membrane permeability that is modulated by the lipid 
composition of the fungal plasma membrane (4). In parallel, K20 has also shown 
inhibitory effects against fungi and is believed to have similar mode of action against 
fungi. Possibly, the amphipathic and polycationic features of FG08 and K20 may 
facilitate the interactions of these compounds with the fungal plasma membrane. The 
interactions could establish hydrogen and ionic bonding between these compounds and 
anionic lipid head groups such as sphingolipids, thus facilitating the fungal plasma 
membrane permeabilization. However, further research is desirable to elucidate such 
bonding and molecular interactions that should provide more understanding into the 
membrane perturbation effects of FG08 and the reasons for the specific targeting of the 
fungal plasma membrane (4). Perhaps, studying the effect of FG08 or K20 on planar lipid 
bilayer membranes consisting of different ratios of lipids, including sphingolipids, will 
help to define the interactions of these compounds with the plasma membrane and the 
effect of membrane composition on their antifungal activity (5). 
109 
 
Finally, I studied the synergistic antifungal interactions of K20 and azoles against 
C. albicans strains and A. flavus. K20 showed strong synergistic antifungal activities with 
azoles against investigated fungal strains. Currently, azoles are the principal and first-line 
drugs used to treat various fungal infections in humans. However, azoles are fungistatic 
rather than fungicidal, thus they are prone to develop resistance by fungi. Combining K20 
and azoles has demonstrated remarkable fungicidal effects against azole-S and azole-R C. 
albicans strains and also has significantly reduced their antifungal MICs comparative to 
when they were used alone. The need for high doses of azoles to combat infections of 
resistant fungal strains can be lowered by combining K20 with azoles. Thus, the 
combination therapy appears promising to reduce side effects on hosts that may incur due 
to application of high doses of azoles to clear infections. This finding presents a new and 
potential avenue for the treatment option of systemic mycoses in medicine. The results of 
K20-azoles combination therapy have further encouraged us to think about the possible 
mechanism of synergistic antifungal action against fungi. Although, the mechanism of 
synergistic interaction with azoles remains unclear at present, it could be presumed that 
both K20 and azoles target different molecular sites in the fungal plasma membrane. This 
may facilitate the swift destabilization of the fungal plasma membrane, thus augmenting 
the fungicidal activity.  
In conclusion, novel aminoglycosides FG08 and K20 are broad-spectrum 
antifungal agents that do not show activity against bacteria or mammalian cells. They 
appear to inhibit fungi by triggering plasma membrane permeability that leads to cell 
death. K20 demonstrated strong antifungal synergy with azoles against different fungal 
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strains. FG08 and K20 appear favorable for their applications as fungicides in agriculture 
and medicine. However, further studies, such as in animal models, are required to 
validate the significance of FG08, K20, and K20-azole combinations as potential 
antifungal therapies. Rigorous studies are warranted to test the efficacies of these drugs 
alone and in combination with azoles using a wide spectrum of clinical isolates of fungi. 
Furthermore, in vivo studies in pharmacodynamics and pharmacokinetics of FG08, K20 
and K20-azole combinations can be performed to establish the rational dosing regimens, 
and identification of antifungal susceptibility breakpoints (6). Overall, these studies set an 
example by offering new approaches of using conventional aminoglycosides 
(antibacterial) in their new form as antifungal agents. Combining these novel antifungals 
with therapeutic antifungals such as azoles, polyenes, and echinocandins may lead to 
development of novel and effective antifungal therapy against fungal infections in 
agriculture and medicine.  
REFERENCES 
1. Chang C-WT, Fosso MY, Kawasaki Y, Shrestha S, Bensaci MF, et al. (2010) 
Antibacterial to antifungal conversion of neamine aminoglycosides through alkyl 
modification. Strategy for reviving old drugs into agrofungicides. J Antibiot 63: 667-
672. 
2. Chang C-WT, Takemoto JY. Aminoglycosides: synthesis and use as antifungals, 
Appl. No. 13/316,720, US 2012/0316125 A1, U.S. Patent and Trademark Office. 
111 
 
3. Lee HB, Kim Y, Kim JC, Choi GJ, Park SH, et al. (2005). Activity of some 
aminoglycoside antibiotics against true fungi, Phytophthora and Pythium species. J 
Appl Microbiol 99:836-843. 
4. Shrestha S, Grilley M, Fosso MY, Chang C-WT, Takemoto JY. (2013). Membrane 
lipid-modulated mechanism of action and non-cytotoxicity of novel fungicide 
aminoglycoside FG08. PLoS ONE 8(9): e73843. doi:10.1371/journal.pone.0073843. 
5. Bensaci MF, Gurnev PA, Bezrukov, SM, Takemoto JY. (2011) Fungicidal activities 
and mechanisms of action of Pseudomonas syringae pv. syringae lipodepsipeptide 
syringopeptins 22A and 25A. Front. Microbiol. 2:216. 
6. Andes D. (2003). Pharmacokinetics and pharmacodynamics in the development of 
antifungal compounds. Curr. Opin. Investig. Drugs 4:991-998. 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
  
113 
 
APPENDIX A 
Chemoenzymatic synthesis of novel aminoglycoside analog, FG08 
FG08 is a novel aminoglycoside analog that is derived from well-known 
aminoglycoside kanamycin B by substitution of a C8 alkyl chain at the 4″- O position of 
ring III. It exhibits broad-spectrum of antifungal activities against a wide range of fungi 
including yeasts, oomycetes, and filamentous fungi but does not inhibit bacteria and 
mammalian cells. FG08 appears attractive for applications as a fungicide in agriculture 
and medicine. Despite these properties, FG08’s development as an antifungal agent is 
limited. Incorporation of the C8 alkyl chain at the kanamycin B 4″- O position is difficult 
and the product yield is low. Since the production of FG08 via chemical synthesis is 
difficult, a chemo-biosynthetic strategy for its production was attempted. For this 
purpose, the glycosyltransferase gene, KanE, from Streptomyces kanamyceticus was 
cloned and expressed in E. coli. Purified enzyme was incubated with the substrates 
neamine (acceptor) and UDP-4-O-octyl glucoside (donor) to make FG08 or FG03. 
However, Kudo et al. 2009 showed a strict substrate specificity of enzyme KanE (also 
known as KanM2) that limited its use to make FG08 or FG03.   
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Bacterial strains, plasmids and culture condition: 
Streptomyces kanamyceticus ATCC12853 was a gift from Dr. Jae Kyung Sohng 
at Department of Pharmaceutical Engineering, Institute of Biomolecule Reconstruction, 
Sun Moon University, Republic of Korea. It was cultured in LB medium at 28oC. The 
plasmid pRSET C (Invitrogen) was used for gene cloning and expression in E. coli. It 
was propagated and maintained in E. coli strain TOP10. Transformants were selected on 
LB plates containing 50-100 μg mL-1 ampicillin. E. coli BL21(DE3) pLysS was used as a 
host for cloning and heterologous expression of protein. Transformants were selected on 
LB plates using 35 μg mL-1 chloramphenicol and 50 μg mL-1 ampicillin. Vector NTI 
software was used to design primers which was later ordered from Integrated DNA 
Technologies. 
Cloning and DNA sequencing of KanE gene 
DNA cloning, ligation, restriction enzyme digestion and other manipulations were 
carried out according to the methods described by Hopwood et al. 2003, Kieser et al. 
2000, Sambrook and Russell, 2001. To obtain the chromosomal DNA, a Streptomyces 
Figure A-1. Schematic diagram of chemo-enzymatic synthesis of FG03. 
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kanamyceticus culture was heat lysed at 100oC for 10 min in sterile water. One µL of cell 
suspension (chromosomal DNA) was used as a template source to amplify kanE gene by 
PCR. Two restriction sites, PstI and EcoRI (NEB), were introduced at 5’ end and 3’end 
of kanE gene fragment using primers 5’-
GCACTGCAGGGCATGCACCTGCTGGTGCG-3’(forward primer) and 5’-
CAGGAATTCTCACAGCCCGATCTCCCGGT-3’(reverse primer), respectively. PCR 
was performed in a thermal cycler (Mastercycler gradient; Eppendorf, Hamburg, 
Germany). Each assay (100 µL) consisted of 200 ng chromosomal DNA, 0.5 µM of each 
primer, and 1x Phusion Master Mix with GC buffer (Phusion High Fidelity PCR Master 
Mix, BioLabs) and 3% DMSO to improve the denaturation of GC-rich template DNA. 
PCR was performed under following conditions; (Total cycles-30, denaturing, annealing 
and extension temperatures were 98oC for 10 sec, 62oC for 30 sec, and 72oC for 1 min 
with additional extension of 10 min). Amplified kanE was inserted into the corresponding 
sites of pRSET C (Invitrogen) to obtain pRSET C-kanE recombinant plasmid (Figure A-
2). The recombinant plasmid was transformed into E.coli BL21(DE3)pLysS by a 
standard heat-shock transformation protocol (Invitrogen) for overexpression.  
KanE gene was successfully isolated and cloned in pRSET C vector and was 
confirmed by sequencing. 
 
 
 
 
 
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-2. (A) PCR amplified kanE gene and bands are shown by arrows lane 1 and 
lane 2). (B) Construction of recombinant plasmid pRSETC + KanE, for the expression of 
kanE in E.coli. 
 
Heterologous expression of KanE in E. coli BL21 (DE3)pLysS 
A single colony harboring pRSETC-kanE was grown overnight in 3 mL of super 
optimal broth (SOB, 2 % tryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5mM KCl, 10 
mM MgCl2, 10 mM MgSO4, and 20 mM glucose) containing ampicillin (50 μg mL-1) and 
chloramphenicol (35 μg mL-1) at 37oC in a shaker incubator 225 rpm. About 2 mL of pre-
culture was used to inoculate 200 mL of fresh SOB medium and grown at 37oC with 225 
rpm until OD600 reached 0.5-1.0. T7 RNA polymerase was induced by the addition of 0.5 
mM IPTG and grown continuously at 18oC for 15-18 h. Cells were harvested by 
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centrifugation at 8000 rpm for 15 min at 4oC. Cell pellets were washed twice by HEPES 
buffer (50 mM, pH 8 containing 10 % glycerol and 1 mM MgCl2) and later resuspended 
in 20 mL HEPES buffer. The cell suspension was lysed by using French press at 4000-
5000 psi. The process was repeated thrice to lyse the cells completely. PMFS (phenyl 
methyl sulfonyl fluoride) and DNAse I were added before each passage through French 
press. The resulting cell extract was centrifuged at 10000 rpm for 30 min at 4oC. A 
portions of the supernatant obtained was fractionated on SDS-PAGE gel to confirm the 
desired protein expression. A protein band of the expected size was observed and a 
sample recovered to be was sent out for analysis by mass spectroscopy at Alphalyse 
(Alphalyse, Palo Alto, CA). The cell extract was loaded onto the Ni-NTA column for 
further purification. 
 
 
 
 
 
 
Figure A-3. SDS-PAGE analysis of KanE expressed in E. coli (A) KanE protein 
expression at different time points (0 h to 24 h). (B) Kan E protein purification from 
soluble fraction (C) KanE protein purification from insoluble fraction.  A band for KanE 
was shown by arrow. LD, ladder; CL, cell lysate; FL, flow through; W1, wash 1; W2, 
Wash 2; E1, elution 1; E2, elution 2. 
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KanE gylcosyltransferase enzyme was successfully expressed in E.coli and was 
confirmed by protein identification 
Immunoblotting 
SDS gels then were transferred to PVDF membranes. Membranes were incubate 
in Tris-buffered saline containing 0.05% Tween-20 and 5% fat free dry milk for 1 h at 
room temperature. Membranes were incubated with primary antibodies Anti His HRP 
(Invitrogen) overnight at 4oC. Signals were visualized using ECL (Pierce, Rockford, IL) 
following manufacturer’s instructions. 
 
 
 
 
 
 
 
 
Figure A-4. Expression of KanE protein in E. coli detected by immunoblotting. 
 
 
 
 
KanE (47KDa) 
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Enzymatic assay of KanE protein 
KanE crude extract was reacted with 5 mM of acceptor (paromamine, neamine) 
and 5 mM of donor UDP-glucose in HEPES-NaOH buffer (50 mM, pH 8, 10 % glycerol, 
1 mM MgCl2). The reaction was continued overnight. The reaction mixture (50 µL) was 
treated with 25µL of 5 % 2,4-Dinitrofluorobenzene (DNFB) (Sigma-Aldritch) in 
methanol, 12.5 µL of DMSO and 2 M of NaOH at 60oC for 1 h. The dinitrophenyl 
derivative reaction products were extracted by addition of ethyl acetate (500 µL). The 
excess ethyl acetate reagent was removed by running the sample under a slow stream of 
N2 gas. The residues obtained were dissolved in 100 µL methanol for HPLC analysis. 
HPLC analysis was performed using a Waters Alliance HPLC (Waters, 
Manchester, UK) equipped with a Symmetry® C18 column (4.6 mm x 75 mm). A mobile 
phase system consists of solvent A: 99.9% and 0.1% trifluoroacetic acid and solvent B: 
99.9 % acetonitrile and 0.1 % trifluoroacetic acid. The elution gradient program was: 100 
% solvent A, 1min; 0-40 % solvent B, 5 min; 40-50 % solvent B, 2 min; 50 - 60 % 
solvent B, 8 min; 60-90 % solvent B, 2min; 90-100 %, 2 min; 100 % solvent B, 1 min. 
Each sample (20 µL) was injected into HPLC. Flow rate used was 1 mL/min. Column 
oven was 40oC and UV absorption at wavelength 350 nm was recorded. 
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APPENDIX B 
The effect of K20 on the dimorphic transition of C. albicans 
C. albicans 10231 cells were maintained by periodic subculturing in yeast extract 
dextrose broth (YPDB) medium. Cultures of yeast cells were maintained in YPDB at 
32oC. To induce mycelial formation, cultures were directly supplemented with 20 % of 
fetal bovine serum (FBS). The dimorphic transition in C. albicans was investigated with 
cultures containing 32 μg mL-1, 64 μg mL-1 and 128 μg mL-1 of K20; 128 μg mL-1 of 
kanamycin B; supplemented with FBS (positive control) and without FBS (negative 
control) which were incubated for 48 h at 32oC (Jung et al., 2007; Sung et al. 2007). The 
dimorphic transition to the mycelial form was detected by phase contrast light 
microscopy (an Olympus IX81 fluorescence microscope using brighfield mode). 
The dimorphic transition of C. albicans from yeast form to mycelial form is 
responsible for pathogenicity, with mycelial shapes being predominantly found during 
the invasion of host tissue. A mycelial form can be induced by temperature, pH, and 
serum (McLain et al., 2000). K20 significantly inhibited the serum-induced mycelial 
transition in comparison to the control and kanamycin A treated yeast cells (Figure B-1). 
 
 
 
 
 
 
121 
 
 
 
 
 
 
 
Figure B-1. The effect of K20 on the dimorphic transition in C. albicans 10231 (A) Yeast 
control without 20 % FBS and K20 (B) Cells treated with only 20 % FBS, (C) Cells 
treated with 16 μg mL-1 of K20 with FBS, and (D) Cells treated with 128 μg mL-1 of 
kanamycin A with FBS. 
  
A 
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APPENDIX C 
Bioactivity of novel aminoglycoside, FG03 
Antifungal activity against Fusarium graminearum, Verticillium spp, Botrytis 
cinerea, Microdochium nivale, Curvularia brachyspora and Pythium ultimum, was 
assessed essentially as described in Lay et al. 2003. Spores were isolated from 
sporulating cultures growing in PDB medium at 25oC by filtration through sterile glass 
wool. Similarly, Candida albicans and Rhodotorula pilimanae were grown in PDA for 48 
h at 35oC. A single colony of each isolate was then used to inoculate 5 mL of PDB and 
incubated for 24 h at 35oC. The cells were titrated using a hemocytometer to attain the 
inoculum size of 2 × 106 CFU mL-1 for both yeasts cells and fungal spores in PDB 
medium. The minimal inhibitory concentrations of FG03 against yeasts and filamentous 
fungi were assayed in 96 well microtiter plates as described in CLSI M-38-A for 
filamentous fungi and CLSI M-27-A2 for yeast. Serial dilutions of FG03 was made in 
sterile 96 well plates (Corning Costar, Corning, NY) in the range of 250 - 0.48 µg mL-1 
and spore suspension was added to make final concentration of 5 x 105 CFU mL-1. The 
plate was incubated at 35oC for 48-72 h. For disk diffusion assays, spores or cells were 
spread on agar plate. Sterile paper disks (0.5 cm diameter) were placed on the surface and 
10 μL of FG03 solutions were applied to the disks. The plates were incubated for 24 to 48 
h and zone of inhibition was measured.  
The effect of FG03 on the growth of the bacterial strains Escherichia coli, and 
Staphylococcus aureus was assayed in microtiter plates. Cells were grown overnight in 
LB broth and diluted to a concentration of 1 × 104 CFU mL-1. Ten microliters of the 
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diluted overnight culture was then added to 190 μL of LB containing 0.48 - 250 µg mL-1 
FG03. Plates were incubated at 37°C without shaking for 16 h. Each test was performed 
in triplicate. 
Table.C-1. Antimicrobial activities of FG03 and kanamycin B. 
Microorganisms MIC (μg mL
-1) 
FG03 kanamycin B 
Bacteria     
E. coli ATCC25922 >250 1.95 
S. aureus >250 0.98 
Filamentous fungi     
Botrytis cinerea 31.3 nda 
Curvularia brachyspora 31.3 nd 
Pythium ultimum 31.3 nd 
Verticillium spp. 15.2 nd 
Microdochium nivale 7.8 nd 
F. graminearum 7.8 >250 
Yeasts     
Candida albicans 62.5 >250 
Rhodotorula pilimanae 62.5 >250 
a not determined. 
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Hemolysis 
Hemolytic activity was determined using methods described by Dartois et al. 
(2005) and Sorensen et al. (1996) with modification. Sheep red blood cells (RBCs) were 
obtained by centrifuging whole blood at 1,000 × g, washed four times with phosphate-
buffered saline (PBS), and resuspended in PBS to a final concentration of 108 
erythrocytes mL-1. The RBC suspension (80 μL) was added to wells of a 96-well 
polystyrene microtiter plate containing 20 μL of serially diluted FG03, FG08, and SRE in 
water. The plate was incubated at 37°C for 60 min. Wells with added deionized water and 
Triton X-100)1 %, w/v) served as negative (blank) and positive controls, respectively 
(data not shown). The percent of hemolysis was calculated using the following equation: 
% hemolysis = [(absorbance of sample) – (absorbance of blank)] ×100/ (absorbance of 
positive control). Fifty percent hemolysis (HD50) values were calculated as the sample 
concentrations required to lyse 50% of the RBC. 
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Figure.C-2. Hemolytic activity of FG03, SRE and FG08 against sheep erythrocytes 
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Mammalian cell growth inhibition assay 
C6181.9 (melanoma) cells were grown in DMEM/Ham’s F12 (1:1) containing 
10% FBS. NIH3T3 cells were grown in DMEM (high glucose) media containing 10% 
FBS in Corning Cell Bind Flasks.  The confluent cells were then trypsionized with 0.25 
% w/v trypsin and resuspended in fresh medium. The cells were transferred into 96-well 
plates at a density of 2 x 105 CFU mL-1. They were mixed with FG03 at final 
concentrations of 10, 20, 50, 100 and 250 µg mL-1 or equivalent volume of sterile double 
distilled water (negative control). The cells were incubated for 24 h at 37oC with 5% CO2 
in a humidified incubator. After 24 h incubation, 10 µL of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (Sigma Aldrich, St. Louis, MO) was added to each well 
and incubated for 4 h. In living cells, mitochondrial reductases convert the MTT 
tetrazolium to formazan, which precipitates. Formazan is dissolved using acidified 
NaDodSO4 (0.01 M HCl) and the A570 using a Gen 5 spectrophotometer (Synergy 4, 
BioTek). Triton X-100 (1 %, v/v) gave complete loss of cell viability and was used as a 
positive control. 
FG03 did not show toxicity to NIH3T3 and C6181.9 cell lines at and above its 
antifungal activity against fungi. 
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Figure. C-3. Mammalian cell cytotoxicities of FG03. (A) MTT cytotoxicities of C8161.9 
melanoma cells (White bars) and (B) NIH3T3 mouse fibroblast cells (Grey bar) with 24 h 
exposure to FG03 at various concentrations. Positive control (0% cell survival) was 
provided by treatment with Triton X-100® (1%, v/v) (black bar). 
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Membrane permeabilization assay 
Spores (5 x 105spore mL-1) of Fusarium graminearum were grown for 18 h in 
PDB broth with continuous agitation. Aliquots (500 µL) were taken and centrifuged for 2 
min at 10,000g. The hyphae were suspended in 10 mM HEPES, pH 7.4, centrifuged 
again, and suspended in 500 µL distilled water (Chang et al. 2010). Hyphae were 
incubated with 20 μg mL-1of FG03 for 1h at 28oC with continuous agitation. The FG03 
treated hyphae were assessed 10 min after addition of 6 µg mL-1 concentration of FITC 
(10 mg mL-1 stock in acetone) (Sigma Aldrich) as previously described (Mangoni et al. 
2004) with slight modification. Glass slides were prepared with 10 μL of each mixture 
and observed in dark-field and fluorescence (using an Olympus MWIB filter, excitation 
and emission wavelength 488-512 nm) modes with an Olympus IX81 fluorescence 
microscope. Data was obtained from at least three independent experiments. 
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Figure C-4. Membrane perturbation effects of FG03 on F. graminearum. 
FITC dye uptake without (A, B), with FG03 (20 μg mL-1) (C, D), and kan B (50 μg mL-1) 
(E, F) exposure for 10 min. Bright-field images (A, C, and E) and fluorescence images 
(B, D, and F). Image B (no FG03 and no kanamycin B) shows no fluorescent cells 
against a fluorescent background. Triton X-100
®
 (1%, v/v) gave 100% dye influx (data 
not shown). 
 
At two times MIC of 20 μg mL-1 for F. graminearum, FG03 caused significant 
FITC cell staining. In contrast, nearly no hyphae were stained when exposed to 
kanamycin B (50 μg mL-1). Unexposed cells were negligibly stained (< 2%). The result 
indicates that FG03 also inhibits fungi by disrupting fungal cell membrane like FG08 and 
K20. 
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